What changed in this filing

/stocks — the workspaceLOADING

Item 8. Financial Statements and Supplementary Data

2023-02-15 compared with 2022-02-15 · 585 added, 632 removed, 657 unchanged (65% of the section changed)

2 unchanged sentences

Index to Audited Consolidated Financial Statements

Report s of Independent Registered Public Accounting Firm (PCAOB ID:

Consolidated Balance Sheets at December 31, 2021 and 2020

Reports of Independent Registered Public Accounting Firm (PCAOB ID:

Consolidated Balance Sheets as of December 31, 2022 and 2021

Consolidated Statements of Operations for the years ended December 31, 2022, 2021 and 2020

31 unchanged sentences

The key assumptions used in the valuation of the financial royalty assets and related interest income are product growth rates applied to forecasted sales in the later years in the royalty life and the royalty duration.

How We Addressed the Matter in Our Audit To test the valuation of the financial royalty assets and related interest income, our audit procedures included, among others, evaluating the methodology and completeness and accuracy of the data used to develop the key assumptions identified above.

How We Addressed the Matter in Our Audit We obtained an understanding, evaluated the design and tested the operating effectiveness of controls related to the valuation of financial royalty assets and related interest income.

This included testing controls over management’s review of the significant assumptions and other inputs used in estimating the royalty duration and product growth rates.

To test the valuation of the financial royalty assets and related interest income, our audit procedures included, among others, evaluating the methodology and completeness and accuracy of the data used to develop the key assumptions identified above.

For example, with the support of statistical modelling specialists, we evaluated management’s statistical methodology for sales growth forecasts and performed sensitivity analysis over the resulting forecasted product sales.

3 unchanged sentences

We also evaluated the related disclosures in the consolidated financial statements.

/s/ Ernst & Young

/s/ Ernst & Young LLP

We have served as the Company’s auditor since 2022.

Dublin, Ireland

New York, New York

February 15, 2023

2 unchanged sentences

Opinion on Internal Control Over Financial Reporting

We have audited Royalty Pharma plc’s (the Company) internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria).

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.

We have audited Royalty Pharma plc’s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria).

In our opinion, Royalty Pharma plc (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive income, shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes and our report dated February 15, 2023 expressed an unqualified opinion thereon.

15 unchanged sentences

Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Ernst & Young

Dublin, Ireland

/s/ Ernst & Young LLP

New York, New York

February 15, 2023

16 unchanged sentences

Available for sale debt securities 226,300 204,400

Investments in non-consolidated affiliates 435,394 454,936

Equity method investments 397,175 435,394

Other assets 29,629 4,145

Total assets $ 16,813,466 $ 17,515,865

Liabilities and equity

Liabilities and shareholders’ equity

Current liabilities

Distribution payable to non-controlling interest $ 107,934 $ 126,366

Distributions payable to legacy non-controlling interests $ 94,803 $ 107,934

Accounts payable and accrued expenses 7,906 5,620

Interest payable 54,162 57,696

Accrued purchase obligation — 110,000

Current portion of long-term debt 997,512 —

Other current liabilities 12,400 —

1 unchanged sentence

Long-term debt 6,118,810 7,096,070

Other liabilities 2,500 —

Total liabilities 7,288,093 7,267,320

10 unchanged sentences

Retained earnings 1,964,689 2,255,179

Non-controlling interest 4,471,951 5,077,036

Non-controlling interests 3,897,223 4,471,951

Accumulated other comprehensive income — 16,491

8 unchanged sentences

2022 2021 2020

Total income and revenues

Income and other revenues

Income from financial royalty assets $ 2,125,096 $ 2,065,083 $ 1,959,975

7 unchanged sentences

General and administrative expenses 227,303 182,826 181,715

Other operating expenses — 65,053 —

Total operating expenses/(income), net 858,748 526,954 ( 808,922 )

Financial royalty asset impairment 615,827 — 65,053

Total operating expenses, net 1,930,150 858,748 526,954

Operating income 307,065 1,430,715 1,595,399

Other expense/(income)

Equity in losses/(earnings) of non-consolidated affiliates 19,490 ( 44,459 ) 32,517

Equity in losses/(earnings) of equity method investees 8,973 19,490 ( 44,459 )

Interest expense 187,961 166,142 157,059

Losses on derivative financial instruments 21,532 42,076 39,138

(Gains)/losses on derivative financial instruments ( 96,610 ) 21,532 42,076

Losses/(gains) on equity securities 33,442 48,066 ( 247,073 )

Unrealized gains on available for sale debt securities ( 17,859 ) ( 18,600 ) —

Losses/(gains) on available for sale debt securities 6,815 ( 17,859 ) ( 18,600 )

Interest income ( 78,335 ) ( 53,535 ) ( 28,379 )

Other non-operating expense/(income), net 5,678 32,821 ( 393 )

Total other expense/(income), net 189,514 ( 106,555 ) 161,757

Other non-operating expense, net 14,755 5,678 32,821

Total other expenses/(income), net 77,001 189,514 ( 106,555 )

Consolidated net income before tax 230,064 1,241,201 1,701,954

1 unchanged sentence

Consolidated net income 230,064 1,241,201 1,701,954

Net income attributable to non-controlling interest 621,473 726,914 112,884

Net income attributable to controlling interest $ 619,728 $ 975,040 $ 2,348,535

Net income attributable to non-controlling interests 187,232 621,473 726,914

Net income attributable to Royalty Pharma plc $ 42,832 $ 619,728 $ 975,040

Earnings per Class A ordinary share (1):

Basic $ 1.49 $ 1.32 N/A

Diluted $ 1.49 $ 1.32 N/A

Basic $ 0.10 $ 1.49 $ 1.32

Diluted $ 0.10 $ 1.49 $ 1.32

Weighted average Class A ordinary shares outstanding (1):

Basic 414,794 375,444 N/A

Diluted 414,802 375,455 N/A

(1) Represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020 following our initial public offering (“IPO”) in the year ended December 31, 2020.

Basic 437,963 414,794 375,444

Diluted 437,972 414,802 375,455

(1) In 2020, amounts represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020 following our initial public offering (“IPO”).

See Note 13–Earnings per Share.

10 unchanged sentences

Reclassification of unrealized gains on available for sale debt securities ( 53,432 ) ( 50,896 ) ( 20,551 )

Total other comprehensive (loss)/income $ ( 39,296 ) $ 66,635 $ 12,348

Other comprehensive (loss)/income $ ( 29,432 ) $ ( 39,296 ) $ 66,635

Comprehensive income $ 200,632 $ 1,201,905 $ 1,768,589

Comprehensive income attributable to non-controlling interest 604,323 739,787 112,884

Comprehensive income attributable to controlling interest $ 597,582 $ 1,028,802 $ 2,360,883

Comprehensive income attributable to non-controlling interests 175,418 604,323 739,787

Comprehensive income attributable to Royalty Pharma plc $ 25,214 $ 597,582 $ 1,028,802

See accompanying notes to these consolidated financial statements.

1 unchanged sentence

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

( In thousands )

( In thousands, except for share amounts )

Ordinary Shares Class B

Ordinary Shares Class R

Redeemable Shares Deferred Shares Additional Paid-In Capital Unitholders’/ Shareholders’ Contributions Retained Earnings Accumulated Other Comprehensive Income/(Loss) Non-Controlling Interest Treasury Interests Total Equity

Redeemable Shares Deferred Shares Additional Paid-In Capital Unitholders’/ Shareholders’ Contributions Retained Earnings Accumulated Other Comprehensive Income Non-Controlling Interests Treasury Interests Total Equity

Shares Amount Shares Amount Shares Amount Shares Amount

Balance at December 31, 2019 — $ — — $ — — $ — — $ — $ — $ 3,282,516 $ 2,825,212 $ 2,093 $ 35,883 $ ( 4,266 ) $ 6,141,438

Distributions — — — — — — — — — — ( 739,276 ) — ( 140,866 ) — ( 880,142 )

Net income — — — — — — — — — — 2,348,535 — 112,884 — 2,461,419

Other comprehensive income/(loss):

Unrealized gains on available for sale debt securities — — — — — — — — — — — 6,159 — — 6,159

Reclassification of loss on interest rate swaps — — — — — — — — — — — 6,189 — — 6,189

Purchase of treasury interests — — — — — — — — — — — — — ( 4,266 ) ( 4,266 )

Balance at December 31, 2019 — $ — — $ — — $ — — $ — $ — $ 3,282,516 $ 2,825,212 $ 2,093 $ 35,883 $ ( 4,266 ) $ 6,141,438

Contributions — — — — — — — — — 307,646 — — 1,174,676 — 1,482,322

20 unchanged sentences

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(In thousands)

( In thousands, except for share amounts )

Ordinary Shares Class B

Ordinary Shares Class R

Redeemable Shares Deferred Shares Additional Paid-In Capital Shareholders’ Contributions Retained Earnings Accumulated Other Comprehensive Income/(Loss) Non-Controlling Interest Treasury Interests Total Equity

Redeemable Shares Deferred Shares Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Income Non-Controlling Interests Treasury Interests Total Equity

Shares Amount Shares Amount Shares Amount Shares Amount

11 unchanged sentences

Balance at December 31, 2021 432,963 $ 43 174,213 $ — 50 $ 63 361,170 $ — $ 3,507,533 $ 2,255,179 $ 16,491 $ 4,471,951 $ ( 2,715 ) $ 10,248,545

Contributions — — — — — — — — — — — 11,596 — 11,596

Distributions — — — — — — — — — — — ( 604,248 ) — ( 604,248 )

Dividends ($ 0.76 per class A ordinary share)

— — — — — — — — — ( 333,322 ) — — — ( 333,322 )

Other exchanges 10,155 1 ( 10,155 ) — — — 10,155 — 156,457 — 1,127 ( 157,494 ) ( 91 ) —

Share-based compensation and related issuances of Class A ordinary shares 48 — — — — — — — 2,170 — — — — 2,170

Net income — — — — — — — — — 42,832 — 187,232 — 230,064

Other comprehensive income/(loss):

Unrealized gains on available for sale debt securities — — — — — — — — — — 14,262 9,738 — 24,000

Reclassification of unrealized gains on available for sale debt securities — — — — — — — — — — ( 31,880 ) ( 21,552 ) — ( 53,432 )

Balance at December 31, 2022 443,166 $ 44 164,058 $ — 50 $ 63 371,325 $ — $ 3,666,160 $ 1,964,689 $ — $ 3,897,223 $ ( 2,806 ) $ 9,525,373

See accompanying notes to these consolidated financial statements.

8 unchanged sentences

Other royalty cash collections 69,891 44,123 18,305

Distributions from non-consolidated affiliates 34,384 42,334 14,059

Distributions from equity method investees 39,142 34,384 42,334

Interest received 24,982 3,135 7,704

2 unchanged sentences

Termination payments on derivative instruments — ( 16,093 ) ( 35,448 )

Ongoing development-stage funding payments ( 6,876 ) ( 20,479 ) ( 83,036 )

Upfront development-stage funding payments ( 193,208 ) ( 5,810 ) —

Development-stage funding payments - ongoing ( 2,106 ) ( 6,876 ) ( 20,479 )

Development-stage funding payments - upfront and milestone ( 175,000 ) ( 193,208 ) ( 5,810 )

Payments for operating and professional costs ( 222,969 ) ( 184,511 ) ( 179,709 )

2 unchanged sentences

Cash flows from investing activities:

Distributions from non-consolidated affiliates 523 15,084 —

Investments in non-consolidated affiliates ( 34,855 ) ( 40,155 ) ( 27,042 )

Distributions from equity method investees — 523 15,084

Investments in equity method investees ( 9,896 ) ( 34,855 ) ( 40,155 )

Purchases of equity securities ( 87,785 ) ( 135,134 ) ( 50,000 )

4 unchanged sentences

Proceeds from sales and maturities of marketable securities 792,341 1,597,851 815,440

Purchase of warrants — — ( 8,840 )

Acquisitions of financial royalty assets ( 1,741,640 ) ( 2,191,502 ) ( 2,182,246 )

Acquisitions of other financial assets ( 21,215 ) — —

Milestone payments — ( 18,600 ) —

2 unchanged sentences

Distributions to shareholders/unitholders — — ( 285,353 )

Distributions to non-controlling interest ( 479,604 ) ( 543,952 ) ( 154,084 )

Distributions to non-controlling interest- other ( 153,800 ) ( 181,135 ) —

Distributions to legacy non-controlling interests - royalty receipts ( 441,963 ) ( 479,604 ) ( 543,952 )

Distributions to legacy non-controlling interests - other ( 31,301 ) ( 20,367 ) ( 67,654 )

Distributions to continuing non-controlling interests ( 144,115 ) ( 133,433 ) ( 113,481 )

Dividends to shareholders ( 333,322 ) ( 285,184 ) ( 112,490 )

Contributions from non-controlling interest- R&D 7,339 8,482 —

Contributions from non-controlling interest- other 36,874 58,957 —

Contributions from legacy non-controlling interests - R&D 1,059 7,339 8,482

Contributions from non-controlling interests - other 6,133 36,874 58,957

Scheduled repayments of long-term debt — — ( 94,200 )

2 unchanged sentences

Debt issuance costs and other ( 1,347 ) ( 13,046 ) ( 46,715 )

Purchase of treasury interests — — ( 4,266 )

Proceeds from issuance of Class A ordinary shares upon IPO, net of offering costs — — 1,908,744

Net cash provided by/(used in) financing activities 385,112 1,487,172 ( 1,191,626 )

Net cash (used in)/provided by financing activities ( 944,856 ) 385,112 1,487,172

Net change in cash and cash equivalents 169,703 532,368 762,481

5 unchanged sentences

Organization and Purpose

Royalty Pharma plc is an English public limited company incorporated under the laws of England and Wales that was created for the purpose of consolidating our predecessor entities and facilitating the IPO of our Class A ordinary shares that was completed in June 2020.

Following our IPO, we control Royalty Pharma Holdings Ltd.

(“RP Holdings”), a private limited company incorporated under the laws of England and Wales and U.K.

Royalty Pharma plc is a public limited company incorporated under the laws of England and Wales that was created to facilitate the IPO of our Class A ordinary shares.

We control Royalty Pharma Holdings Ltd (“RP Holdings”), a private limited company incorporated under the laws of England and Wales and U.K.

tax resident, through our ownership of RP Holdings’ Class A ordinary shares (the “RP Holdings Class A Interests”) and RP Holdings’ Class B ordinary shares (the “RP Holdings Class B Interests”).

We conduct our business through RP Holdings and its subsidiaries and include RP Holdings and its subsidiaries in our consolidated financial statements.

RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (“RPI 2019 ICAV”), which is an Irish collective asset management entity formed to facilitate our Exchange Offer Transactions (defined below), and is the successor to Royalty Pharma Investments, an Irish unit trust (“Old RPI”), for accounting and financial reporting purposes.

RP Holdings is the sole owner of Royalty Pharma Investments 2019 ICAV (“RPI 2019 ICAV”), which is an Irish collective asset management entity, and is the successor to Royalty Pharma Investments, an Irish unit trust (“Old RPI”).

RP Holdings is owned by RPI US Partners 2019, LP, a Delaware limited partnership, RPI International Holdings 2019, LP, a Cayman Islands exempted limited partnership (together, the “Continuing Investors Partnerships”), and Royalty Pharma plc.

Old RPI is a unit trust established in August 2011 under the laws of Ireland and authorized by the Central Bank of Ireland pursuant to the Unit Trusts Act, 1990.

Prior to the Exchange Offer Transactions, Old RPI was owned by various partnerships (the “Legacy Investors Partnerships”).

RP Management, LLC (the “Manager”), a Delaware limited liability company, is an external adviser which is responsible for our management.

RP Management (Ireland) Ltd.

(“RP Ireland”), is the manager of Old RPI and equivalent to the board of directors of a company or general partner of a partnership and is responsible for the day to day operations of Old RPI.

Its functions can be delegated to third parties.

RP Ireland delegated responsibility for investment management of Old RPI to its parent company, the Manager, in accordance with the investment objectives and policies of Old RPI.

Prior to the Exchange Offer (defined below), Old RPI was owned by various partnerships (the “Legacy Investors Partnerships”).

RP Management, LLC (the “Manager”), a Delaware limited liability company, is responsible for our management, including our day-to-day operations, pursuant to advisory and management agreements (collectively, the “Management Agreement”) .

“Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Royalty Pharma plc and its subsidiaries on a consolidated basis.

After the consummation of the Reorganization Transactions (defined below) and before the consummation of the IPO, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to RPI 2019 ICAV.

Prior to the Reorganization Transactions, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Old RPI.

After the consummation of the Exchange Offer (defined below) and before the consummation of the IPO, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to RPI 2019 ICAV.

Prior to the Exchange Offer, “Royalty Pharma,” the “Company,” “we,” “us” and “our” refer to Old RPI.

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry.

We fund innovation in the biopharmaceutical industry both directly and indirectly—directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.

Reorganization Transactions

In connection with our IPO, we consummated an exchange offer on February 11, 2020 (the “Exchange Date”).

Through the exchange offer, investors representing 82 % of the aggregate limited partnership in the Legacy Investors Partnerships, exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships.

The exchange offer transaction together with (i) the concurrent incurrence of indebtedness under our new credit facility and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the “Exchange Offer Transactions.”

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

As a result of the Exchange Offer Transactions, we own, through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (“RPI Intermediate FT”), an 82 % economic interest in Old RPI.

Through our 82 % indirect ownership of Old RPI, we are legally entitled to 82 % of the economics of Old RPI’s wholly-owned subsidiaries, RPI Finance Trust, a Delaware statutory trust (“RPIFT”) and RPI Acquisitions (Ireland), Limited (“RPI Acquisitions”), an Irish private limited company, and 66 % of Royalty Pharma Collection Trust, a Delaware statutory trust (“RPCT”).

Exchange Offer Transactions

We consummated an exchange offer on February 11, 2020 (the “Exchange Offer”) to facilitate the IPO.

Through the Exchange Offer, investors which represented 82 % of the aggregate limited partnership in the Legacy Investors Partnerships exchanged their limited partnership interests in the Legacy Investors Partnerships for limited partnership interests in the Continuing Investors Partnerships.

The Exchange Offer together with (i) the concurrent incurrence of indebtedness under senior credit facilities and (ii) the issuance of additional interests in Continuing Investors Partnerships to satisfy performance payments payable in respect of assets acquired prior to the date of the IPO are referred to as the “Exchange Offer Transactions.”

As a result of the Exchange Offer Transactions, we own indirectly an 82 % economic interest in Old RPI through our subsidiary RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (“RPI Intermediate FT”).

We are entitled to 82 % of the economics of Old RPI’s wholly-owned subsidiar y RPI Finance Trust, a Delaware statutory trust (“RPIFT”) , and, an Irish private limited company, and 66 % of Royalty Pharma Collection Trust, a Delaware statutory trust (“RPCT”).

The remaining 34 % of RPCT is owned by the Legacy Investors Partnerships and Royalty Pharma Select Finance Trust, a Delaware statutory trust (“RPSFT”), which is wholly owned by Royalty Pharma Select, an Irish unit trust.

From the Exchange Date until the expiration of the Legacy Investors Partnerships’ investment period on June 30, 2020 (the “Legacy Date”), the Legacy Investors Partnerships were offered to participate proportionately in any investment made by Old RPI.

From the date of the Exchange Offer until the expiration of the Legacy Investors Partnerships’ investment period on June 30, 2020 (the “Legacy Date”), the Legacy Investors Partnerships could participate proportionately in any investment made by Old RPI.

Following the Legacy Date, Old RPI ceased making new investments and each of Old RPI and the Legacy Investors Partnerships became legacy entities.

Since the Legacy Date, we have made and plan to make new investments through our subsidiaries, including RPI Intermediate FT.

As part of the Exchange Offer Transactions, the Legacy Investors Partnerships and RPI Intermediate FT entered into new credit facilities in the amount of $ 1.3 billion and $ 6.0 billion, respectively, the proceeds of which were used to repay the $ 6.3 billion outstanding debt of RPIFT and, in the case of RPI Intermediate FT, were also available to be used to fund investments.

As part of the new credit facilities, RPI Intermediate FT repaid $ 5.2 billion, its pro rata portion of RPIFT’s outstanding debt and accrued interest.

Since the Legacy Date, we have made and plan to make new investments through our subsidiaries.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

As part of the Exchange Offer, the Legacy Investors Partnerships and RPI Intermediate FT entered into senior credit facilities in the amount of $ 1.3 billion and $ 6.0 billion, respectively, the proceeds of which were used to repay the $ 6.3 billion outstanding debt of RPIFT and, in the case of RPI Intermediate FT, were also available to be used to fund investments.

As part of the senior credit facilities, RPI Intermediate FT repaid $ 5.2 billion, its pro rata portion of RPIFT’s outstanding debt and accrued interest.

RPIFT also terminated all outstanding interest rate swaps in connection with the debt refinancing.

Prior to, and as a condition precedent to the closing of the IPO, various reorganization transactions became effective, including the following:

• the Exchange Offer Transactions (as described above);

• the execution of a new management agreement with the Manager (the “Management Agreement”).

We refer to these transactions collectively as the “Reorganization Transactions.”

As Old RPI is our predecessor for financial reporting purposes, we have recorded Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date.

The references in the following notes for the periods prior to the Exchange Date refer to the financial results of Old RPI for the same periods.

On June 18, 2020, we completed our IPO on the Nasdaq Global Select Market under the ticker symbol “RPRX”, in which we issued 89,334 thousand Class A ordinary shares at a price to the public of $ 28.00 per Class A ordinary share, of which 71,652 thousand Class A ordinary shares and 17,682 thousand Class A ordinary shares were offered by the Company and selling shareholders, respectively.

We used the net proceeds from the IPO to acquire RP Holdings Class A Interests and, as a result, we own 100 % of RP Holdings Class A Interests.

Upon consummation of the IPO, certain of the Continuing Investors agreed to exchange, pursuant to the Exchange Offer Transactions, interests in the Continuing Investors Partnerships represented by their ownership of 294,176 thousand RP Holdings Class B Interests into an aggregate of 294,176 thousand Class A ordinary shares of Royalty Pharma plc.

We used the net proceeds from the IPO to acquire 100 % of RP Holdings Class A Interests.

Upon consummation of the IPO, certain of the Continuing Investors agreed to exchange, according to the Exchange Offer Transactions, interests in the Continuing Investors Partnerships represented by their ownership of 294,176 thousand RP Holdings Class B Interests into an aggregate of 294,176 thousand Class A ordinary shares of Royalty Pharma plc.

Upon completion of the exchange, Royalty Pharma plc indirectly owned 294,176 thousand RP Holdings Class B Interests.

1 unchanged sentence

As a result, the Continuing Investors Partnerships held a number of our Class B ordinary shares equal to the number of RP Holdings Class B Interests indirectly held by them at such time which are exchangeable on a one -for-one basis for Class A ordinary shares of Royalty Pharma plc.

Refer to Note 12–Shareholders’ Equity for additional information.

Summary of Significant Accounting Policies

1 unchanged sentence

The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period.

Actual results may differ from those estimates.

The precise extent to which the COVID-19 pandemic will impact our operational and financial performance will depend on various factors.

To date, certain marketers of some of our portfolio products have commented that the performance of these products have been impacted by the COVID-19 pandemic.

However, the COVID-19 pandemic has not resulted in a material effect to our results of operations and liquidity and we do not believe it is reasonably likely to in the future.

Due to the nature of our business, the effect of the COVID-19 pandemic may not be fully reflected in certain of our results of operations until future periods.

The COVID-19 pandemic has not had a material impact on our results of operations and liquidity and we do not believe it is reasonably likely to in the future.

Basis of consolidation

1 unchanged sentence

We consolidate based upon evaluation of our power, through voting rights or similar rights, to direct the activities of another entity that most significantly impact the entity’s economic performance.

For consolidated entities where we own or are exposed to less than 100% of the economics, we record Net income attributable to non-controlling interest in our consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.

Following management’s determination that a high degree of common ownership existed in Royalty Pharma both before and after the Exchange Date, Royalty Pharma recognized Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the Exchange Date.

Prior to the Exchange Offer Transactions, our only historical non-controlling interest was attributable to a de minimis interest in RPCT held by RPSFT.

As a result of the Exchange Offer Transactions in February 2020, a new non-controlling interest was created related to the Legacy Investors Partnerships’ ownership of approximately 18 % in Old RPI.

Following the consummation of our IPO in June 2020, two new non-controlling interests were created:

(1) a non-controlling interest related to the Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of the RP Holdings Class B Interests, which amounted to approximately 29 % as of December 31, 2021, and (2) a non-controlling interest related to RPI EPA Holdings, LP (“EPA Holdings”), an affiliate of the Manager through its ownership of the RP Holdings’ Class C ordinary share (the “RP Holdings Class C Special Interest”).

Income will not be allocated to the latter non-controlling interest until certain conditions are met.

For consolidated entities where we own or are exposed to less than 100% of the economics, we record Net income attributable to non-controlling interests in our consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.

Following management’s determination that a high degree of common ownership existed in Old RPI both before and after the date of the Exchange Offer, Royalty Pharma recognized Old RPI’s assets and liabilities at the carrying value reflected on Old RPI’s balance sheet as of the date of the Exchange Offer.

In 2022, we became an indirect owner of an 82 % economic interest in RPI ICAV, which previously was owned directly by Old RPI.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

We report four non-controlling interests:

(1) the Legacy Investors Partnerships’ ownership of approximately 18 % in Old RPI and RPI ICAV and (2) a de minimis interest in RPCT held by RPSFT (together, the “legacy non-controlling interests”).

The legacy non-controlling interests are the only historical non-controlling interests existing prior to our IPO.

Additionally, following the consummation of our IPO, we also report non-controlling interests related to (3) the Continuing Investors Partnerships’ ownership in RP Holdings through their ownership of RP Holdings Class B Interests and (4) RPI EPA Holdings, LP’s (“EPA Holdings”) ownership of the RP Holdings’ Class C ordinary share (the “RP Holdings Class C Special Interest”).

The Continuing Investors Partnerships are referred to as the “continuing non-controlling interests.” Income will not be allocated to EPA Holdings until certain performance conditions are met.

All intercompany transactions and balances have been eliminated in consolidation.

Adjustment to prior period presentation

In connection with the preparation of our condensed consolidated interim financial statements for the three months ended September 30, 2020, we identified an adjustment to the classification of our short-term investments on our consolidated balance sheets, as of December 31, 2019, based on the original maturity dates of the investments.

The adjustment resulted in an increase of $ 37.5 million to Marketable securities and a corresponding decrease to Cash and cash equivalents on the consolidated balance sheet as of December 31, 2019.

In addition, the adjustment resulted in an increase of $ 388.0 million and $ 350.5 million in cash activity related to Purchases of marketable securities and Proceeds from sales and maturities of marketable securities , respectively, within Net cash used in investing activities for the year ended December 31, 2019, with a net impact on net cash flow from investing of $ 37.5 million.

The adjustment had no effect on our reported total income and revenues, consolidated net income, total assets, or shareholders’ equity for any period.

In addition, the adjustment does not impact net cash provided by operating activities in any period.

We evaluated the adjustment and determined that, based on quantitative and qualitative analysis, it was not material to the consolidated financial statements as of and for the year ended December 31, 2019.

Reclassification

Certain prior period amounts have been reclassified to conform to the current period presentation.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Concentrations of credit risk

Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets and receivables.

Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, available for sale debt securities, financial royalty assets, derivatives and receivables.

Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations.

Our cash and cash equivalents and marketable securities balances at December 31, 2021 and 2020 were held with State Street and Bank of America.

Our cash and cash equivalents and marketable securities balances as of December 31, 2022 and 2021 were held with State Street , Bank of America, US Bank and Scotiabank .

Our primary operating accounts significantly exceed the Federal Deposit Insurance Corporation limits.

The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived.

The products in which we hold royalties are marketed by leading industry participants, including, among others, AbbVie, Bristol Myers Squibb, Gilead, Johnson & Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche and Vertex.

For the years ended December 31, 2021 and 2020, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 32 % and 27 % of our current portion of Financial royalty assets, net , respectively, representing the largest individual receivable balance in both years.

The products in which we hold royalties are marketed by leading industry participants, including, among others, Vertex, Biogen, AbbVie, Johnson & Johnson, Merck & Co, Pfizer, Astellas, Novartis, and Gilead.

As of December 31, 2022 and 2021, Vertex, as the marketer and payor of our royalties on the cystic fibrosis franchise, accounted for 31 % and 32 % of our current portion of financial royalty assets, respectively, and represented the largest individual marketer and payor of our royalties.

We monitor the financial performance and creditworthiness of the counterparties to our royalty agreements so that we can properly assess and respond to changes in their credit profile.

1 unchanged sentence

Segment information

Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluates financial performance and makes overall operating decisions.

Our chief operating decision maker is our Chief Executive Officer who reviews financial information presented on a consolidated basis to allocate resources, evaluate financial performance and make overall operating decisions.

As such, we concluded that we operate as one single reportable segment, which is primarily focused on acquiring biopharmaceutical royalties .

2 unchanged sentences

These acquisitions entitle us to receive a portion of income from the sale of patent-protected biopharmaceutical products by unrelated biopharmaceutical companies.

For the majority of our royalties, our rights are protective in nature.

For the majority of our royalties, our rights are protective and passive in nature.

In other words, we do not own the intellectual property and we do not have the right to commercialize the underlying products.

These contractual cash flow rights have yield components that most closely resemble loans and are classified as financial royalty assets .

In the limited instances where we possess rights to exploit the underlying patents, rights to the intellectual property related to the biopharmaceutical products, or the ability to influence the amount or duration of future royalty payments, these royalties are classified as intangible assets.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The cost of an intangible royalty asset is amortized over the expected life of the asset on a straight-line basis .

Financial royalty assets, net

1 unchanged sentence

Therefore, such financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 Imputation of Interest .

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount.

The effective interest rate is reviewed and adjusted each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows.

Income is calculated by multiplying the carrying value of the financial royalty asset by the effective interest rate.

The carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by the interest income accrual and decreased by cash receipts in the period to arrive at the ending balance.

The effective interest rate is recalculated each reporting period as differences between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows.

Income is calculated by multiplying the carrying value of the financial royalty asset by the periodic effective interest rate.

The carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by accrued interest income and decreased by cash receipts in the period to arrive at the ending balance.

If the ending balance is greater than the net present value of the expected future cash flows, a provision is recorded to reduce the asset balance to the net present value.

The provision is recorded through the income statement as Provision for changes in expected cash flows from financial royalty assets and the carrying value of Financial royalty assets, net is presented net of the cumulative allowance for changes in expected future cash flows.

The application of the prospective approach to measure financial royalty assets requires management’s judgment in forecasting the expected future cash flows of the underlying royalties.

The application of the prospective approach to measure our financial royalty assets at amortized cost requires management’s judgment in forecasting the expected future cash flows of the underlying royalties.

The amounts and duration of forecasted expected future cash flows used to calculate and measure interest income are largely impacted by sell-side equity research analyst coverage, commercial performance of the product, and royalty duration, each discussed in further detail below .

1 unchanged sentence

Forecasts of expected future cash flows are developed from sales projections of the underlying biopharmaceutical products as published in sell-side equity research analyst reports.

In projecting future cash flows, our policy is to rely on sell-side research analysts’ consensus sales forecasts for a product to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones.

These forecasts are based on input from internal and external market research that analyzes factors such as growth in global economies, industry trends and product life cycles.

When royalty-bearing biopharmaceutical products have no coverage, limited sell-side equity research analyst coverage or where sell-side equity research analyst consensus sales estimates are not available for the full term of the royalty, particularly for the later years in a product’s life, management uses reasonable judgment to make assumptions about the growth or decline in the sales of these products based on historical data, market trends and management’s own expertise.

For the majority of the portfolio of financial royalty assets, management utilizes statistical curves based on historical trends to project future sales when sell-side equity research analyst consensus sales estimates end or are not available for the full term of the royalty.

In other cases, management may develop and apply growth rate estimates from existing sell-side equity research analysts’ consensus sales forecasts to project future sales for products that cannot be modeled through the statistical curves, such as those where the entrance of a biosimilar is expected to impact future sales.

Based on the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications.

In projecting future cash flows, our policy is to rely on sell-side research analysts’ consensus sales forecasts to derive annual sales projections for each financial royalty asset over the periods for which we are entitled to royalties or milestones.

These forecasts are based on market research that analyzes factors such as growth in global economies, industry trends and product life cycles.

For the majority of the portfolio of financial royalty assets, management utilizes statistical curves to project future sales for a portion of the royalty duration when sell-side equity research coverage ends or when estimates are not available for the duration of the royalty.

The statistical curves are modelled from a combination of historical trends and available sell-side equity research analyst consensus sales estimates .

In limited cases when the statistical curve is not used, management may develop and apply growth rate estimates from existing sell-side equity research analysts’ consensus sales forecasts to project future sales for products.

Based o n the level of detail in sell-side equity research analyst models, management can also be required to apply assumptions to the sales forecasts to estimate the quarterly and geographical allocation from annual sales projections and, for franchised products, to estimate the product mix and pricing mix, or to exclude from projections sales forecasts for unapproved products or indications.

Our contractual royalty terms, rates, and any milestones are then applied to the adjusted sales projections to calculate the expected royalty or milestone payments over the term of the financial royalty asset’s life, forming the basis for our forecast of expected future cash flows used to calculate and measure interest income .

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

• Commercial performance.

The approval of a product for use in new indications can extend the date through which we are entitled to royalties or milestones on that product.

For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and whose sales were previously not reflected in expected future cash flows.

For certain financial royalty assets, such as the cystic fibrosis franchise, we are entitled to royalties on approved combination products and may be entitled to royalties on future combination products, which, once approved, create new cash flow streams which were not initially contemplated and for which sales were previously not reflected in expected future cash flows.

We generally do not recognize income from, or forecast sales for, unapproved products or indications.

1 unchanged sentence

Both the new cash flow streams and the cessation of cash flow streams related to a product’s performance in the market over the royalty term can materially affect our forecast of expected future cash flows.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

• Royalty duration.

The duration of a royalty can be based on a number of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the time in the product’s life cycle at which we acquire the royalty.

Royalty duration varies by geography as United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms.

The duration of a royalty can be based on a variety of factors, such as regulatory and marketing approval dates, patent expiration dates, the number of years from first commercial sale, the first date of manufacture of the patent-protected product, the entry of generics or a contractual date arising from litigation, which are all impacted by the point in time in the product’s life cycle at which we acquire the royalty.

Royalty duration varies by geography as the United States, European Union and other jurisdictions may be subject to different country-specific patent protection terms or exclusivity based on contractual terms.

Products may be covered by a number of patents and, for products whose royalty term is linked to the existence of valid patents, management is required to make judgments about the patent providing the strongest patent protection to align the period over which management forecasts expected future cash flows to the royalty term.

3 unchanged sentences

As part of the preparation of the forecasted expected future cash flows, which relies on the sources and variables discussed above, management is required to make assumptions around the following forecast inputs:

(1) estimates of the duration of the royalty, which includes consideration of the strength of patent protection and anticipated entry of generics, (2) product growth rates and sales trends in outer years, (3) the product and pricing mix for franchised products, and (4) the geographical allocation of annual sales data from sell-side equity research analysts’ models.

(1) estimates of the duration of the royalty, which includes consideration of the strength of patent protection and anticipated entry of generics, (2) product growth rates and sales trends in outer years, generally projected through statistical curves, (3) the product and pricing mix for franchised products, and (4) the geographical allocation of annual sales data from sell-side equity research analysts’ models.

The most sensitive of these assumptions relates to management’s estimate of the royalty duration in the final years of an asset’s life.

4 unchanged sentences

Additionally, royalty payments may occasionally continue beyond the estimated royalty expiration date for such reasons we cannot foresee such as excess inventory in the channel or additional scope of patent protection identified after expiry, including royalties we may become entitled to from new indications, new compounds, or for new regulatory jurisdictional approvals .

The current portion of Financial royalty assets, net represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears.

The current portion of financial royalty assets represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter and for which the estimates are derived from the latest external publicly available sell-side equity research analyst reports, reported in arrears.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Cumulative allowance and Provision for changes in expected cash flows from financial royalty assets

We evaluate financial royalty assets for impairment on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period.

If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record a provision for the change in expected cash flows.

If the effective interest rate is lower for the current period than the prior period, and if the gross cash flows have declined (expected and collected), we record provision expense for the change in expected cash flows.

The provision is measured as the difference between the financial royalty asset’s amortized cost basis and the net present value of the expected future cash flows, calculated based on the prior period’s effective interest rate.

The amount recognized as provision expense increases the financial royalty asset’s cumulative allowance, which reduces the net carrying value of the financial royalty asset .

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance for the increase in the present value of cash flows expected to be collected, resulting in a non-cash credit to the provision line on the income statement.

In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance, resulting in non-cash provision income recorded through the Provision for changes in expected cash flows from financial royalty assets on the consolidated statements of operations.

We also recalculate the amount of accretable yield to be received based on the revised remaining future cash flows.

The adjustment to the accretable yield is treated as a change in estimate and is recognized prospectively over the remaining life of the financial royalty asset by adjusting the effective interest rate used to calculate income .

Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the Financial royalty assets, net line item on the consolidated balance sheet, are accompanied by corresponding changes to the provision.

Movements in the cumulative allowance for changes in expected future cash flows, which forms part of the Financial royalty assets, net line item on the consolidated balance sheets, are accompanied by corresponding provision income or expense.

Amounts not expected to be collected are written off against the allowance at the time that such a determination is made.

2 unchanged sentences

We account for this non-cash true-up at the end of the royalty term as either Provision for changes in expected cash flows from financial royalty assets or as Income from financial royalty assets on the consolidated statements of operations .

Income from financial royalty assets

We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected.

The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets.

After acquisition of a financial royalty asset, if we are not able to reliably estimate expected cash flows for a product or if we have not completed the required funding obligations payable over time for an approved product, a financial royalty asset is placed in non-accrual status (e.g., for royalties from products that have not yet received FDA approval or for accelerated royalties).

Such financial royalty assets are held at cost and no income is recognized until the reasonable expectation of the timing of the future cash flows to be collected is available or until funding obligations payable over time for an approved product are complete.

We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress, clinical trial results, and publicly available information around regulatory discussions and approval status.

An impairment loss is recognized if, based on current information and events, it is probable that we will be unable to collect amounts due according to the contractual terms of the financial royalty asset, and the amount of loss can be reasonably estimated.

When royalties are received for financial royalty assets that have been fully amortized, such income is recognized as Other royalty income.

Allowance for current expected credit losses

1 unchanged sentence

Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) which requires earlier recognition of credit losses.

We now recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights.

We recognize an allowance for current expected credit losses on our portfolio of financial royalty assets with limited protective rights.

The credit loss allowance is estimated using the probability of default and loss given default method.

The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the probability of default of the marketers responsible for paying our royalties and the resulting loss given default.

The allowance for current expected credit losses is presented net within the non-current portion of Financial royalty assets, net on the consolidated balance sheets.

Any subsequent movement in the allowance for credit losses is recorded as part of the Provision for changes in expected future cash flows from financial royalty assets on the consolidated statements of operations.

Refer to Note 7 –Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for further information.

Intangible royalty assets, net

Currently, our only intangible royalty assets are the Januvia and Janumet (“DPP-IV”) patents.

The DPP-IV patents are finite-life intangible royalty assets whose cost is amortized using the straight-line method over the expected lives of the patents, the majority of which terminate at various dates through 2022.

The amortization period commenced concurrent with the sale of the product underlying the royalty asset.

The allowance for current expected credit losses is presented net within the non-current portion of financial royalty assets on the consolidated balance sheets.

Any subsequent provision for credit losses is recorded as part of the Provision for changes in expected future cash flows from financial royalty assets on the consolidated statements of operations .

Income from financial royalty assets

We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected.

The accretable yield is recognized as income at the effective rate of return over the expected life of financial royalty assets.

An acquisition of a royalty on a development-stage product classified as a financial royalty asset is generally placed in non-accrual status.

In these cases, the financial royalty asset is held at cost and no income is recognized until we are able to reliably estimate expected cash flows, generally when the product receives regulatory approval.

We evaluate such financial royalty assets held at cost for impairment based on, among other factors, a review of development progress and publicly available information around regulatory discussions , clinical trial results and approval status.

An impairment loss is recognized if, based on available information, it is prob able that we will be unable to recover the carrying value of the financial royalty asset held at cost, and the amount of loss can be reasonably estimated.

When royalties are received for financial royalty assets that have been fully amortized, such income is recognized as Other royalty income.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Management reviews the performance of intangible royalty assets periodically for impairment as required by ASC 360-10, Property, Plant, and Equipment - Overall .

The test for recoverability is performed by comparing the carrying value of the intangible royalty asset with the estimated future undiscounted cash flows generated through royalty payments from sales of the underlying DPP-IV products.

When evaluating indicators of impairment, we consider factors such as competitive environment and the product’s life cycle stage, recent and prospective sales trends, collectability concerns, and any potential rebate chargebacks that may occur at the end of a royalty’s term.

An impairment loss is recognized if the carrying value of the intangible royalty asset is not recoverable and its carrying amount exceeds its fair value.

Revenue from intangible royalty assets and Accrued royalty receivable

We earn royalties on sales by our licensees of DPP-IV products covered under patents that we own.

Revenue from intangible royalty assets

We earn royalties on sales by our licensees of Januvia and Janumet (“DPP-IV”) products covered under patents that we own.

We do not have future performance obligations under these license arrangements.

Royalty revenue from sales of DPP-IV products is recognized in the period the product is sold.

However, under the license agreements, licensees generally provide royalty reports and payments on a one quarter lag.

Thus, the accrued royalty receivable is based on an analysis of historical royalties received and sell-side equity research analysts’ projected sales, adjusted for any changes in estimates.

Royalty-bearing sales are net of certain rebates and other discounts, as permitted under the terms of the license agreements.

Because rebates are generally invoiced and paid in arrears by the marketer, royalty reports often reflect deductions in current periods for rebates related to prior periods which we do not have the ability to estimate.

Critical estimates that could cause a change in estimated future cash flows include changes in product demand and market growth assumptions, a change in the pricing strategy of the marketer or reimbursement coverage, and changes in country-specific contractual or patent expiry dates.

Actual royalty receipts may differ from estimates and any differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically on the basis of royalty receipts.

Milestone payments

Certain acquisition agreements provide for future incoming or outgoing contingent payments based on the commercial, regulatory or clinical performance of the related biopharmaceutical product generally over a multi-year period.

For purposes of measuring income from financial royalty assets, commercial milestones payable or receivable are reflected in the cash flows used to forecast expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts’ consensus sales forecasts.

For purposes of measuring income from financial royalty assets, commercial milestones payable or receivable are reflected in the forecast ed expected future cash flows in the period in which the milestone criteria is projected to be satisfied based on sell-side equity research analysts’ consensus sales forecasts.

Milestones based on regulatory approval or clinical criteria are generally not reflected in the expected future cash flows until such approval is achieved.

We assess all milestone payments to determine whether we must account for these arrangements as derivatives instruments under ASC 815 – Derivatives and Hedging .

Amounts related to outgoing contingent milestone payments are not considered contractual obligations as they are contingent on the successful completion of the defined milestones.

Payments under these agreements generally become due and payable upon achievement of certain commercial milestones, and when the contingency is resolved .

Financial instruments

Certain financial instruments reflected in the consolidated balance sheets, (e.g., cash and cash equivalents, certain other assets, accounts payable and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature.

The fair values of financial instruments other than Financial royalty assets, net are determined through a combination of management estimates and information obtained from third parties using the latest market data.

The fair value of financial instruments is determined utilizing the valuation techniques appropriate to the type of instrument as discussed in Note 5 – Fair Value Measurements and Financial Instruments.

Financial instruments and Fair value measurements

Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities, royalty interests and long-term debt.

Cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and certain royalty interests are reported at their respective fair values on our consolidated balance sheets.

Outstanding borrowings and non-current financial royalty assets are reported at their amortized costs on our consolidated balance sheets, for which fair values are disclosed.

The remaining financial instruments are reported on our consolidated balance sheets at amounts that approximate fair values.

For financial instruments carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety.

We determine the fair value of assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:

Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.

Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.

Cash and cash equivalents and Marketable securities

4 unchanged sentences

Equity securities and Available for sale debt securities

Our equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings.

Our equity securities represent investments in publicly traded equity securities.

Available for sale debt securities are measured at fair value.

The unrealized change in fair value of available for sale debt securities for which we elected the fair value option is recorded within Unrealized gains on available for sale debt securities on the consolidated statements of operations.

The unrealized change in fair value for the Biohaven Series A Preferred Share is included in Accumulated other comprehensive income (“AOCI”) and are reclassified to earnings as interest income is recognized.

Interest income is recognized when we can reliably estimate forecasted cash flows.

A decline in the market value of any available for sale debt security below its cost that is deemed to have resulted from a credit loss results in a reduction in carrying amount to fair value and is recognized in earnings.

The determination of whether a decline in fair value below the amortized cost basis for an available for sale debt security has resulted from a credit loss requires significant judgment and requires consolidation of available quantitative and qualitative evidence in evaluating the potential impairment.

Factors evaluated to determine whether a decline in the fair value below the amortized cost basis has resulted from a credit loss include:

the extent to which fair value is less than the amortized cost basis, adverse conditions related to the security, an industry, or geographic area, the payment structure of the security, failure of the issuer to make scheduled payments, any changes to the rating of the security by a rating agency, the remaining payment terms of the security, prepayment speeds, the financial condition of the issuer expected defaults, our intent not to sell, and an evaluation as to whether it is more likely than not that we will have to sell before recovery of the cost basis.

Assumptions associated with these factors are subject to future market and economic conditions, which could differ from management’s assessment.

We may elect to apply the fair value option for certain investments in debt securities where the fair value option better aligns with the economics of such investment.

Our equity securities primarily consist of investments in publicly traded equity securities.

The equity securities are measured and recorded at fair value with unrealized gains and losses recorded in earnings.

Investments classified as available for sale debt securities are recorded at fair value.

We may elect to apply the fair value option for available for sale debt securities where the fair value option better aligns with the economics of the investment.

Upon such election, the entire investment is measured at fair value on a recurring basis, with movements in fair value recognized in earnings.

For available for sale debt securities for which we did not elect the fair value option, the unrealized change in fair value is recorded within in Accumulated other comprehensive income (“AOCI”) and is reclassified to earnings as interest income is recognized when we can reliably estimate forecasted cash flows.

All derivatives are measured at fair value on the consolidated balance sheets with movements in fair value recognized in earnings.

Prior to 2017, RPIFT applied hedge accounting to its interest rate swap agreements.

Upon the discontinuation of hedge accounting, the AOCI previously recorded on the cash flow hedges was reversed out of other comprehensive income in line with terms of the associated swap contract until the termination of all of our interest rate swaps in February 2020.

This reclassification adjustment is shown on the consolidated statements of operations as part of Losses on derivative financial instruments .

Investment in non-consolidated affiliates

Investments in entities that provide us with the ability to exercise significant influence, but not a controlling financial interest, and where we are not the primary beneficiary are accounted for under the equity method or as equity securities for which we have elected the fair value option with the movements in fair value of the equity securities recognized within Losses/(gains) on equity securities in the consolidated statements of operations.

Investments accounted for under the equity method are initially recorded at fair value.

1 unchanged sentence

Subsequently, we recognize through earnings our proportionate share of the investee’s net income or loss, net of any adjustment to reflect the amortization of basis differences.

We generally record our share of the results of our investees one quarter in arrears within Equity in losses/(earnings) of non-consolidated affiliates in the consolidated statements of operations.

The investment is reflected as Investments in non-consolidated affiliates on the consolidated balance sheet.

We generally record our share of the results of our investees one quarter in arrears within Equity in losses/(earnings) of equity method investees in the consolidated statements of operations.

The investment is reflected as Equity method investments on the consolidated balance sheets .

We have variable interests in entities formed for the purposes of entering into co-development arrangements for potential biopharmaceutical products (the “Avillion entities”).

2 unchanged sentences

Management continuously assesses whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of one or more of its investees .

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

When we have committed to provide further support to the investee through capital call commitments and the investment has been reduced to zero, we provide for additional losses, resulting in a negative equity method investment, which is presented as a liability on the consolidated balance sheets .

2 unchanged sentences

In accordance with ASC 730, Research and Development , we account for the funded amounts as R&D expense when we have the ability to obtain the results of the R&D, the transfer of financial risk is genuine and substantive and, at the time of entering into the transaction, it is not yet probable that the product will receive regulatory approval.

We may pay funded amounts upfront or over time as the underlying products undergo clinical trials.

If these conditions are not met, we may record the funded amounts as a financial royalty asset.

We may fund R&D upfront or over time as the underlying products undergo clinical trials.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Royalty payments owed to the Company on successfully commercialized products generated from R&D arrangements are recognized as Other royalty income in the same period in which the sale of the product occurs.

Fixed or milestone payments receivable based on the achievement of contractual criteria for products arising out of our R&D arrangements are also recognized as Other royalty income in the period that the milestone threshold is met.

Fixed or milestone payments receivable based on the achievement o f contractual criteria for pr oducts arising out of our R&D arrangements are also recognized as Other royalty income in the period that the milestone threshold is met.

Milestone thresholds are typically not triggered until after all funding obligations have been completed .

1 unchanged sentence

Neither the U.S.

Internal Revenue Code (“the Code”) nor the applicable Treasury regulations provide a general definition of what constitutes being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance.

Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U.

federal income tax for the years presented in the consolidated financial statements.

While we believe we are not engaged in the conduct of a trade or business within the United States or subject to U.S.

taxation in that regard, we are subject to U.

federal withholding tax on certain fixed or determinable annual or periodical gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code.

Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax.

We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not be subject to any U.S.

withholding taxes on U.S.-source royalty payments.

Consequently, because we believe that we are not engaged in the conduct of a trade or business within the United States and our subsidiaries are eligible for benefits under the U.S.-Ireland tax treaty, we do not record a provision for income taxes.

While we do not currently record a provision for income taxes, we are party to certain arrangements that will give rise to a tax provision in the future.

We currently have funding arrangements in place that allow our counterparties to draw on capital over a prescribed period of time.

When such funding arrangements are drawn and we begin to recognize income from these funding arrangements, such activities will be subject to U.S.

taxation and we will record a provision for income taxes in accordance with ASC 740, Income Taxes .

We also entered into an arrangement with MSCI during 2021 as discussed in Note 16 – Related Party Transactions that will become subject to U.S.

taxation when we begin to recognize revenue from this transaction.

Internal Revenue Code (“the Code”) nor the applicable Treasury regulations provide a general definition of what constitutes as being engaged in the conduct of a trade or business within the United States, and the limited case law on the subject does not provide definitive guidance.

Based on our periodic assessment, we believe that we are not engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U.S.

income taxes with respect to effectively connected income for the years presented in the consolidated financial statements .

We have funding arrangements in place where our counterparties have drawn on capital or are allowed to draw on capital over a prescribed period of time.

Income from these funding arrangements are subject to U.S.

taxation and we record a provision for U.S.

income taxes in accordance with ASC 740, Income Taxes, with respect to this income .

Additionally, we entered into an arrangement with MSCI during 2021 as discussed in Note 16–Related Party Transactions that will be subject to U.S.

taxation when we begin to recognize revenue .

At that time, we will record a provision for U.S.

income taxes in accordance with ASC 740, Income Taxes , with respect to revenue from the MSCI transaction.

We operate so as to be treated solely as resident in the U.K.

4 unchanged sentences

corporation tax on receipt of dividends or other income distributions in respect of shares held by them, unless those dividends or other distributions fall within an exempt class.

We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI, should fall within such an exempt class and therefore should not be subject to U.K.

We believe that dividends received by us from RP Holdings, and dividends received by RP Holdings from RPI 2019 ICAV, should fall within such an exempt class and therefore should not be subject to U.K.

corporation tax.

1 unchanged sentence

income taxes with respect to the dividends received from RP Holdings or with respect to the dividends received by RP Holdings from RPI .

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

We are also subject to the U.K.’s “controlled foreign companies” rules (the “U.K.

CFC Rules, broadly, can impose a charge to U.K.

CFC Rules, broadly, applies to U.K.

tax resident companies that have, alone or together with certain other persons, interests in a non-U.K.

4 unchanged sentences

Certain non-U.K.

entities in which we hold a greater than 25% interest, including RPI (which is Irish tax resident) and Old RPI (which is Irish tax resident and which is held indirectly by us through our participation in RP Holdings) , will be Controlled Foreign Companies for U.K.

entities in which we hold a greater than 25% interest, including RPI 2019 ICAV (which is an Irish tax resident) and Old RPI (which is an Irish tax resident and is held indirectly by us through our participation in RP Holdings), are considered Controlled Foreign Companies for U.K.

tax purposes.

We are therefore required to apply the CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis.

We do not expect material U.K.

corporation tax charges to arise under the U.K.

CFC Rules in respect of our royalty assets and we therefore do not record a provision for U.K.

income taxes.

We are therefore required to apply the U.K.

CFC Rules in respect of our direct and indirect interests in these entities on an ongoing basis.

We do not expect material tax charges to arise under the U.K.

CFC Rules with respect to our direct and indirect interests in these entities and we therefore do not record a provision for U.K.

income taxes related to this matter .

Other taxation matters

We are subject to U.S.

federal withholding tax on certain fixed or determinable annual or periodic gains, profits and income, such as royalties from sources within the United States, unless reduced or eliminated under an applicable tax treaty or provision of the Code.

Generally, this tax is imposed by withholding 30% of the payments, or deemed payments, that are subject to this tax.

We believe our subsidiaries are eligible for benefits under the U.S.-Ireland income tax treaty, and, under that treaty, are not subject to any U.S.

withholding taxes on U.S.-source royalty payments.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Earnings per share

Basic earnings per share (“EPS”) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period.

Diluted EPS is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued.

Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares contingently issuable to RPI EPA Holdings, LP (“EPA Holdings”) related to Equity Performance Awards and unvested restricted share units (“RSUs”) issued under our 2020 Independent Director Equity Incentive Plan (“Equity Incentive Plan”).

Basic earnings per share (“EPS”) is calculated by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period.

Diluted EPS is calculated by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued.

Our Class B ordinary shares, Class R redeemable shares and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities.

Our outstanding Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a one -for-one basis.

Potentially dilutive securities also include Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards and unvested RSUs issued under our 2020 Independent Director Equity Incentive Plan.

We include potentially dilutive shares in the denominator to compute diluted EPS if (i) the inclusion of the ordinary shares is dilutive for the respective reporting periods, and (ii) contingencies are satisfied as of the end of the reporting period for ordinary shares that are contingently issuable.

1 unchanged sentence

There were no Class A ordinary shares or Class B ordinary shares outstanding prior to June 16, 2020;

therefore, no earnings per share information has been presented for any period prior to that date.

Recently adopted accounting standards

In June 2016, the FASB issued a new accounting standard that amends the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model (ASU 2016-13).

Accordingly, these financial assets are presented at the net amount expected to be collected.

This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model.

With certain exceptions, adjustments are applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption.

Upon the January 1, 2020 adoption of ASU 2016-13, we recorded a cumulative adjustment to Retained earnings of $ 192.7 million to recognize an allowance for current expected credit losses on our financial royalty assets.

In August 2018, the FASB issued a new accounting standard that eliminates, adds and modified certain disclosures requirements for fair value measurements under Topic 820 (ASU 2018-13).

The ASU modifies the disclosures by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers.

The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income/(loss).

We adopted this standard as of January 1, 2020 with no material impact on our consolidated financial statements and accompanying notes.

therefore, no earnings per share information have been presented for any period prior to that date.

Available for Sale Debt Securities

Cytokinetics Commercial Launch Funding

On January 7, 2022, we entered into a long-term funding agreement with Cytokinetics, Incorporated (“Cytokinetics”) to support further development of aficamten and potential commercialization of omecamtiv mecarbil, both development-stage products.

During 2022, we amended the funding agreement to increase the required draw amount, extend the draw period and modify the return for the second and third tranches.

As part of the funding agreement, we agreed to provide capital (“Cytokinetics Commercial Launch Funding”) of up to $ 300 million, which is comprised of five tranches, including an initial tranche of $ 50 million that was funded upon closing.

Cytokinetics is required to draw $ 50 million if a certain contingency is met and has the option to draw the remaining $ 200 million upon the occurrence of certain regulatory and clinical development milestones (“Cytokinetics Funding Commitments”).

Each tranche has an interest-free and payment-free period of six calendar quarters, followed by 34 calendar quarters of installment re-payments totaling 1.9 times the amount drawn, except for the second and third tranches, which each total 2.0 times the amount drawn.

As of December 31, 2022, we expect $ 125 million of the optional $ 200 million to remain available under the Cytokinetics Commercial Launch Funding due to the likelihood that certain regulatory milestones will not be met by March 31, 2023.

We elected the fair value option to account for the Cytokinetics Commercial Launch Funding, recorded within Available for sale debt securities on the consolidated balance sheets, as it most accurately reflects the nature of the funding arrangement.

The Cytokinetics Funding Commitments, which include options and forwards over the subsequent tranches, are recognized at fair value within Other liabilities as of December 31, 2022 on the consolidated balance sheets.

The changes in the fair value of the funded Cytokinetics Commercial Launch Funding and the Cytokinetics Funding Commitments are recorded within Losses/(gains) on available for sale debt securities in the consolidated statements of operations.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Available for Sale Debt Securities

MorphoSys Development Funding Bonds

On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys AG (“MorphoSys”) to support its acquisition of Constellation Pharmaceuticals, Inc.

which closed on July 15, 2021.

As part of the funding agreement, we agreed to provide MorphoSys up to $ 350 million of capital (the “Development Funding Bonds”), of which MorphoSys was required to draw a minimum of $ 150 million.

Our commitment to fund at least $ 150 million of the Development Funding Bonds was recognized as the Development Funding Bond Forward as of December 31, 2021.

In September 2022, we funded $ 300 million of the Development Funding Bonds, which represents additional funding of $ 150 million above the minimum funding commitment (“Additional Funding”) and the Development Funding Bond Forward was settled at the same time.

We expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years , with the first payment beginning in the fourth quarter of 2024.

As of December 31, 2022, we have no remaining funding commitment under the Development Funding Bonds.

We elected the fair value option to account for the funded amount of the Development Funding Bonds and the Development Funding Bond Forward as it most accurately reflects the nature of the instruments.

The funded amount of the Development Funding Bonds and the Development Funding Bond Forward are recorded within Available for sale debt securities on the consolidated balance sheets.

The changes in the fair values of the funded amount of the Development Funding Bonds and the Development Funding Bond Forward are recorded within Losses/(gains) on available for sale debt securities in the consolidated statements of operations.

Biohaven Preferred Shares

Series A Biohaven Preferred Shares

On April 5, 2019, RPIFT funded the purchase of 2,495 Series A Biohaven Preferred Shares from Biohaven Pharmaceutical Holding Company Ltd.

(“Biohaven”) at a price of $ 50,100.00 per preferred share, for a total of $ 125.0 million (the “First Tranche”).

On April 5, 2019, RPIFT purchased 2,495 Series A Biohaven Preferred Shares from Biohaven Pharmaceutical Holding Company Ltd (“Biohaven”) at a price of $ 50,100 per preferred share, for a total of $ 125 million.

The approval of Nurtec ODT by the U.S.

Food and Drug Administration (“FDA”) in February 2020 results in a payment due to us of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments beginning in the three months ended March 31, 2021 through the three months ended December 31, 2024.

In the three months ended March 31, 2021, we began receiving payments from the quarterly redemption of the Series A Biohaven Preferred Shares.

If Biohaven effects any change of control event, then we will have the option to cause Biohaven to redeem, in a single payment, any outstanding Series A Biohaven Preferred Shares at a price equal to two times the original purchase price of the Series A Biohaven Preferred Shares.

Biohaven may redeem at their election, any outstanding Series A Biohaven Preferred Shares, in a single payment, at a price equal to two times the original purchase price.

In the event that Biohaven defaults on any obligation to redeem Series A Biohaven Preferred Shares when required, the redemption amount shall accrue interest at the rate of 18 % annually until the redemption price for such unredeemed Series A Biohaven Preferred Shares is paid in full, subject to applicable law.

If any such default continues for at least one year , we will be entitled to convert all unredeemed Series A Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date.

The Series A Biohaven Preferred Shares are classified as Available for sale debt securities in our consolidated balance sheets.

The unrealized change in the fair value of the Series A Biohaven Preferred Shares is recorded within Unrealized gains on available for sale debt securities on the consolidated statements of comprehensive income.

Food and Drug Administration (“FDA”) in February 2020 resulted in a payment due to us of two times the original purchase price of the Series A Biohaven Preferred Shares beginning in the first quarter of 2021 through the fourth quarter of 2024.

In the first quarter of 2021, we began receiving payments of $ 15.6 million from the quarterly redemption of the Series A Biohaven Preferred Shares.

The Series A Biohaven Preferred Shares were classified as Available for sale debt securities on the consolidated balance sheet as of December 31, 2021.

The unrealized changes in the fair value of the Series A Biohaven Preferred Shares were recorded within Unrealized gains on available for sale debt securities in the consolidated statements of comprehensive income.

In 2022, 2021 and 2020, $ 53.4 million, $ 50.9 million and $ 20.6 million of unrealized gains were reclassified from other comprehensive income to Interest income on the consolidated statements of operations, respectively.

Series B Biohaven Preferred Shares

On August 7, 2020 we entered into a Series B Biohaven Preferred Share Purchase Agreement (“Series B Biohaven Preferred Share Agreement”) with Biohaven where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $ 50,100 per preferred share (the “Commercial Launch Preferred Equity”), for a total of $ 200.0 million payable on a quarterly basis between the three months ended March 31, 2021 and the three months ended December 31, 2024.

Our commitment to purchase the Series B Biohaven Preferred Shares is recognized as the Series B Forwards.

In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030 at a price equal to approximately 1.8 times the original purchase price of the Series B Biohaven Preferred Shares.

If Biohaven effects any change of control event, then we will have the option to cause Biohaven to issue to us all unissued Series B Biohaven Preferred Shares and to redeem, in a single payment, any outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the Series B original issue price per share.

Biohaven may redeem at their election, any outstanding Series B Biohaven Preferred Shares, in a single payment, at a price equal to approximately 1.8 times the original issue price for the Series B Biohaven Preferred Shares.

In the event that Biohaven defaults on any obligation to redeem Series B Biohaven Preferred Shares, the redemption amount shall accrue interest on the applicable original issue price at the rate of 18 % annually until the redemption price for such unredeemed Series B Biohaven Preferred Shares is paid in full, subject to applicable law.

If any such default continues for at least one year , we will be entitled to convert any or all unredeemed Series B Biohaven Preferred Shares into common shares equal to the redemption price, plus accrued interest, divided by the five-day volume-weighted trading price immediately preceding the conversion date.

In the three months ended March 31, 2021, we began purchasing the Series B Biohaven Preferred Shares.

As of December 31, 2021, we have acquired 1,406 shares of Series B Biohaven Preferred Shares.

We have elected the fair value option to account for the Series B Forwards and the Series B Biohaven Preferred Shares, which are recorded in aggregate on the consolidated balance sheets as Available for sale debt securities .

On August 7, 2020, we entered into the Series B Biohaven Preferred Share Purchase Agreement (“Series B Biohaven Preferred Share Agreement”) with Biohaven where we committed to acquire 3,992 shares of Series B Biohaven Preferred Shares at a price of $ 50,100 per preferred share (the “Commercial Launch Preferred Equity”), for a total of $ 200 million payable on a quarterly basis between the first quarter of 2021 and the fourth quarter of 2024.

Our commitment to purchase the Series B Biohaven Preferred Shares was recognized as the Series B Forwards.

We elected the fair value option to account for the Series B Biohaven Preferred Shares and the Series B Forwards, which were recorded within Available for sale debt securities on the consolidated balance sheet as of December 31, 2021.

We believe the fair value option most accurately reflects the nature of these instruments.

The unrealized change in fair value of the Series B Biohaven Preferred Shares and Series B Forwards is recorded within Unrealized gains on available for sale debt securities on the consolidated statements of operations.

The changes in fair value of the Series B Biohaven Preferred Shares and Series B Forwards were recorded within Losses/(gains) on available for sale debt securities in the consolidated statements of operations.

In 2022, 2021 and 2020, we recognized gains of $ 122.5 million, $ 13.5 million and $ 18.6 million, respectively, related to Series B Biohaven Preferred Shares within Losses/(gains) on available for sale debt securities in the consolidated statements of operations.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

MorphoSys Development Funding Bonds

On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys AG (“MorphoSys”) to support MorphoSys’ acquisition of Constellation Pharmaceuticals, Inc.

(“Constellation”), which closed on July 15, 2021.

As part of the funding agreement, we agreed to provide MorphoSys up to $ 350 million of capital (the “Development Funding Bonds”), which MorphoSys may draw over a one-year period from the close of its acquisition of Constellation.

MorphoSys is required to draw a minimum of $ 150 million.

As of December 31, 2021, MorphoSys has not drawn any amount under the Development Funding Bonds.

Our commitment to fund at least $ 150 million of the Development Funding Bonds is recognized as the Development Funding Bond Forward.

Once drawn, we expect to receive a return of 2.2 times the amount funded on the Development Funding Bonds payable on a quarterly basis over nine years , with the first payment beginning two years after the funding.

We have elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument.

The Development Funding Bond Forward is recorded within Available for sale debt securities in our consolidated balance sheet.

The unrealized change in fair value of the Development Funding Bond Forward is recorded within Unrealized gains on available for sale debt securities on the consolidated statements of operations.

On October 3, 2022, Pfizer Inc.

(“Pfizer”) acquired Biohaven, which was a change of control event that accelerated the issuance of all unissued Series B Biohaven Preferred Shares and the redemption of all outstanding Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares.

We purchased all remaining unissued Series B Biohaven Preferred Shares simultaneously with the redemption of all outstanding Series B Biohaven Preferred Shares at a price equal to approximately 1.8 times the original purchase price.

The Series A Biohaven Preferred Shares were redeemed at a price equal to two times the original purchase price.

As of December 31, 2022, we no longer hold any Series A Biohaven Preferred Shares or Series B Biohaven Preferred Shares.

The table below summarizes our available for sale debt securities recorded at fair value as of December 31, 2022 and 2021 (in thousands):

Cost (1) Unrealized Gains Fair Value Current Assets Non-Current Assets Total

Cost Unrealized (Losses)/Gains Fair Value Current Assets Non-Current Assets Current Liabilities Non-Current Liabilities Total

As of December 31, 2022

Series A Biohaven Preferred Shares $ 134,068 $ 29,432 $ 163,500 $ 66,000 $ 97,500 $ 163,500

Series B Biohaven Preferred Shares 70,441 19,759 90,200 — 90,200 90,200

Series B Forwards — 12,300 12,300 — 12,300 12,300

Development Funding Bond Forward — 4,400 4,400 — 4,400 4,400

Debt securities (1) $ 359,400 $ ( 131,800 ) $ 227,600 $ 1,300 $ 226,300 $ — $ — $ 227,600

Funding commitments (2) ( 9,400 ) 6,900 ( 2,500 ) — — ( 2,500 ) ( 2,500 )

Total available for sale debt securities $ 350,000 $ ( 124,900 ) $ 225,100 $ 1,300 $ 226,300 $ — $ ( 2,500 ) $ 225,100

As of December 31, 2021

Series A Biohaven Preferred Shares $ 145,647 $ 68,753 $ 214,400 $ 69,984 $ 144,416 $ 214,400

Series B Forwards — 18,600 18,600 — 18,600 18,600

Debt securities (3) $ 204,509 $ 49,191 $ 253,700 $ 66,000 $ 187,700 $ — $ — $ 253,700

Forwards (4) — 16,700 16,700 — 16,700 — — 16,700

Total available for sale debt securities $ 204,509 $ 65,891 $ 270,400 $ 66,000 $ 204,400 $ — $ — $ 270,400

(1) Cost for Series A Biohaven Preferred Shares represents amortized cost.

Cost for Series B Biohaven Preferred Shares represents the amounts paid to purchase the instruments.

There were no costs associated with the Series B Forwards and Development Funding Bond Forward.

(1) The cost associated with the funded Cytokinetics Commercial Launch Funding reflects the fair value on the purchase date.

The cost of the Development Funding Bonds represents the amounts funded.

(2) The cost associated with the Cytokinetics Funding Commitments represents the fair value on the purchase date.

(3) The cost for the Series A Biohaven Preferred Shares represents amortized cost.

The cost for the Series B Biohaven Preferred Shares represents the

amounts paid to purchase the instruments.

These instruments were fully redeemed during 2022.

(4) There are no costs associated with the forwards.

Derivative Instruments

3 unchanged sentences

We do not enter into derivative instruments for trading or speculative purposes.

Treasury rate lock contracts

In June 2021, we entered into treasury rate lock contracts with notional amounts totaling $ 600.0 million to manage the impact of fluctuations in the underlying benchmark interest rate associated with the 2021 Notes (as further discussed and defined in Note 11–Borrowings).

The treasury rate lock contracts were not designated as hedge instruments.

All of the treasury rate lock contracts had collateral requirements.

The treasury rate lock contracts were unwound and settled in connection with the issuance of the 2021 Notes and the resulting net loss was recognized in earnings in the year ended December 31, 2021.

We paid $ 16.1 million in July 2021 to terminate our treasury rate lock contracts.

Milestone Acceleration Option

On August 7, 2020, we entered into an expanded funding agreement with Biohaven, which included the Series B Biohaven Preferred Share Agreement, to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones payable over time.

Upon a change of control event, we have the option to cause Biohaven to accelerate the payment of zavegepant milestone payments, if triggered, in a lump sum amount (“Milestone Acceleration Option”).

The Milestone Acceleration Option is an embedded derivative instrument for which the associated fair value was not material prior to the second quarter of 2022, when Pfizer announced its intended acquisition of Biohaven.

On October 3, 2022, Pfizer acquired Biohaven and we elected to accelerate the zavegepant success-based milestone payments, if triggered, in a lump sum amount.

As of December 31, 2022, the fair value of the Milestone Acceleration Option was $ 96.6 million, of which $ 86.2 million was recorded within Other current assets and $ 10.5 million was recorded within Other assets on the consolidated balance sheets.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Treasury rate lock contracts

The treasury rate lock contracts had collateral requirements and were not designated as hedge instruments.

We paid $ 16.1 million in July 2021 to terminate our treasury rate lock contracts in connection with the issuance of the 2021 Notes.

Interest rate swaps

1 unchanged sentence

We paid $ 35.4 million to terminate these swaps and reclaimed $ 45.3 million of collateral that was held by the respective counterparties.

During the years ended December 31, 2020 and 2019, we recorded unrealized losses of $ 10.9 million and $ 72.6 million, respectively, on interest rate swaps in the consolidated statements of operations.

We did not enter into any interest rate swaps subsequent to the February 2020 termination discussed above and as of December 31, 2021, we do not hold any interest rate swap contracts.

We did not enter into any interest rate swaps subsequent to the February 2020 termination discussed above.

Epizyme put option and warrant

1 unchanged sentence

(“Epizyme”) of $ 100.0 million.

Under the terms of the agreement with Epizyme, we made an upfront payment of $ 100.0 million for (1) shares of Epizyme common stock, (2) a warrant to purchase an additional 2.5 million shares of Epizyme common stock at $ 20 per share over a three-year term and (3) Epizyme’s royalty on sales of Tazverik in Japan payable by Eisai Co., Ltd (“Eisai”).

Under the terms of the agreement with Epizyme, we made an upfront payment of $ 100.0 million in exchange for (1) shares of Epizyme common stock, (2) a warrant to purchase an additional 2.5 million shares of Epizyme common stock at $ 20 per share over a three-year term and (3) Epizyme’s royalty on sales of Tazverik in Japan payable by Eisai Co., Ltd (“Eisai”).

In addition, Epizyme had an 18 month put option to sell an additional $ 50.0 million of its common stock to RPIFT at then prevailing prices, not to exceed $ 20 per share.

On December 31, 2019, Epizyme notified RPIFT of its intention to exercise the put option.

As a result, we recorded a forward purchase contract equal to the difference between the market value and exercise price of $ 11.5 million within Other assets on the consolidated balance sheets at December 31, 2019.

We recorded the put option as a forward purchase contract as of December 31, 2019.

The exercise of the put option was settled in February 2020.

The warrant was recognized at fair value of $ 5.4 million within Other assets on the consolidated balance sheets at December 31, 2020.

The fair value of the warrant was no t material as of December 31, 2021.

We recorded an unrealized loss of $ 5.4 million, an unrealized loss of $ 25.4 million and an unrealized gain of $ 22.0 million on derivative contracts related to the change in fair value of the warrant on the consolidated statements of operations for the years ended December 31, 2021, 2020 and 2019, respectively.

As of December 31, 2021, the fair value of the warrant was immaterial.

The warrant remained unexercised and was terminated upon Ipsen’s acquisition of Epizyme in 2022.

Summary of derivatives and reclassifications

The tables below summarize the change in fair value of the derivatives for the years ended December 31, 2021, 2020 and 2019 and the line items within the consolidated statements of operations where the gains or losses on these derivatives are recorded (in thousands).

The tables below summarize the changes in fair value of the derivatives for 2022, 2021 and 2020 and the line items within the consolidated statements of operations where the gains or losses on these derivatives were recorded (in thousands):

Years Ended December 31, Location on Consolidated Statements of Operations

2 unchanged sentences

Interest rate swaps:

Amount of loss reclassified from accumulated other comprehensive income into income $ — $ 4,066 $ 6,189 Losses on derivative financial instruments

Change in fair value of interest rate swaps — ( 73 ) 16,954 Losses on derivative financial instruments

Interest expense/(income) — 114 ( 9,565 ) Interest expense

Amount of loss reclassified from accumulated other comprehensive income into net income $ — $ — $ 4,066 (Gains)/losses on derivative financial instruments

Change in fair value of interest rate swaps — — ( 73 ) (Gains)/losses on derivative financial instruments

Interest expense — — 114 Interest expense

Derivatives not designated as hedging instruments

Interest rate swaps:

Change in fair value of interest rate swaps — 6,908 49,472 Losses on derivative financial instruments

Interest expense/(income) — 408 ( 2,681 ) Interest expense

Change in fair value of warrant 5,439 25,375 ( 21,977 ) Losses on derivative financial instruments

Forward purchase contract:

Change in fair value of forward purchase contract — 5,800 ( 11,500 ) Losses on derivative financial instruments

Treasury rate lock contracts:

Change in fair value of treasury rate lock contracts 16,093 — — Losses on derivative financial instruments

Change in fair value of interest rate swaps — — 6,908 (Gains)/losses on derivative financial instruments

Interest expense — — 408 Interest expense

Changes in fair value of other instruments:

Warrant — 5,439 25,375 (Gains)/losses on derivative financial instruments

Forward purchase contract — — 5,800 (Gains)/losses on derivative financial instruments

Treasury rate lock contracts — 16,093 — (Gains)/losses on derivative financial instruments

Milestone Acceleration Option ( 96,610 ) — — (Gains)/losses on derivative financial instruments

(1) Certain interest rate swaps were previously designated as cash flow hedges.

4 unchanged sentences

Fair Value Measurements and Financial Instruments

Fair value hierarchy

We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value as follows:

Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.

Prices or valuation that require inputs that are both significant to the fair value measurement and unobservable.

Our financial instruments consist primarily of cash and cash equivalents, marketable securities, equity securities, derivatives, available for sale debt securities and long-term debt.

Cash and cash equivalents, marketable securities, equity securities, derivatives and available for sale debt securities are reported at their respective fair values in our consolidated balance sheets.

For financial instruments which are carried at fair value, the level in the fair value hierarchy is based on the lowest level of inputs that is significant to the fair value measurement in its entirety.

Long-term debt and financial royalty assets are reported at their amortized costs in our consolidated balance sheets but for which fair values are disclosed.

The remaining financial instruments are reported in our consolidated balance sheets at amounts that approximate current fair values.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table summarizes financial assets and financial liabilities that we measured at fair value on a recurring basis at the dates indicated, classified in accordance with the fair value hierarchy described above (in thousands):

The following table summarizes assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

As of December 31, 2022 As of December 31, 2021

5 unchanged sentences

Marketable securities

Corporate debt securities — — — — — 32,754 — 32,754

Commercial paper — — — — — 207,457 — 207,457

Certificates of deposit — 11,501 — 11,501 — 374,415 — 374,415

government securities — 12,920 — 12,920 — — — —

Available for sale debt securities

Debt securities (1) — — 1,300 1,300 — — 66,000 66,000

Derivative instruments (2) — — 86,150 86,150 — — — —

Total current assets $ 5,068 $ 24,421 $ 87,450 $ 116,939 $ 598,253 $ 636,823 $ 66,000 $ 1,301,076

1 unchanged sentence

Available for sale debt securities

Debt securities (1) — — 226,300 226,300 — — 187,700 187,700

Forwards (3) — — — — — — 16,700 16,700

Warrant (2) — — — — — 5,439 — 5,439

Derivative instruments (2) — — 10,460 10,460 — — — —

Royalty at fair value (4) — — 14,500 14,500 — — — —

Total non-current assets $ 103,876 $ — $ 259,732 $ 363,608 $ 226,787 $ — $ 247,413 $ 474,200

(1) The balance as of December 31, 2021 includes Series B Forwards and the Development Funding Bond Forward, recorded within Available for sale debt securities in the consolidated balance sheet, related to our obligations to fund acquisitions of the Series B Biohaven Preferred Shares and $ 150 million of the Development Funding Bonds, respectively.

The balance as of December 31, 2020 relates to Series B Forwards, recorded within Available for sale debt securities in the consolidated balance sheet.

See Note 3–Available for Sale Debt Securities for additional discussion.

(2) Related to the Epizyme transaction as described in Note 4–Derivative Instruments and recorded in Other assets in the consolidated balance sheets as of December 31, 2021 and 2020.

The fair value of the warrant was no t material as of December 31, 2021.

Available for sale debt securities

Funding commitments (5) — — ( 2,500 ) ( 2,500 ) — — — —

Total non-current liabilities $ — $ — $ ( 2,500 ) $ ( 2,500 ) $ — $ — $ — $ —

(1) As of December 31, 2022, amounts reflect the fair value of the funded portion of the Cytokinetics Commercial Launch Funding and the funded portion of the Development Funding Bonds.

As of December 31, 2021, amounts reflect the fair value of the Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares.

(2) Reflects the fair value of the Milestone Acceleration Option .

(3) Reflects the fair value of our obligations to fund the acquisitions of the Series B Biohaven Preferred Shares and our obligations to fund the Development Funding Bonds.

(4) Recorded within Other assets on the consolidated balance sheet.

See Note 9–Non-Consolidated Affiliates for additional discussion.

(5) Related to the fair value of the Cytokinetics Funding Commitments.

For 2022 and 2021, we recognized losses of $ 39.1 million and $ 41.4 million, respectively, on equity securities still held as of December 31, 2022.

There were no gains or losses in 2020 associated with the equity securities still held as of December 31, 2022.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the years ended December 31, 2021, 2020 and 2019, we recognized a loss of $ 60.1 million, a loss of $ 85.4 million and a gain of $ 104.4 million, on equity securities still held as of December 31, 2021, respectively.

The tables presented below summarize the change in the combined fair value (current and non-current) of Level 3 financial instruments, which relate to equity securities and available for sale debt securities, including the underlying debt securities and related forwards (in thousands).

Years Ended December 31,

Equity Securities

Balance at the beginning of the year $ — $ —

Purchases 35,120 —

Gains on equity securities 7,893 —

Balance at the end of the year $ 43,013 $ —

Years Ended December 31,

Debt Securities

The table presented below summarizes the change in the combined fair value (current and non-current) of Level 3 financial instruments (in thousands):

Year Ended December 31, 2022 Year Ended December 31, 2021

Equity Securities Debt Securities Forwards Funding Commitments Derivative Instruments Royalty at Fair Value Equity Securities Debt Securities Forwards

Balance at the beginning of the year $ 43,013 $ 253,700 $ 16,700 $ — $ — $ — $ — $ 214,400 $ 18,600

Purchases (1) 28,785 479,559 — — — 21,215 35,120 70,441 —

Unrealized gains on available for sale debt securities (1) 12,900 52,725

Settlement of forwards (2) 18,459 —

Transfer to Level 2 — ( 184,005 )

Transfer from Level 2 (3) — 198,526

Unrealized gains on available for sale debt securities (1) — 15,874

Redemption ( 62,500 ) —

Balance at the end of the year $ 253,700 $ 214,400

Years Ended December 31,

Balance at the beginning of the year $ 18,600 $ —

Unrealized gains (4) 16,559 18,600

Gains/(losses) on initial recognition (2) — 600 — ( 9,400 ) — — — — —

(Losses)/gains on equity securities ( 22,634 ) — — — — — 7,893 — —

Gains on derivative financial instruments — — — — 96,610 — — — —

Unrealized gains on available for sale debt securities included in other comprehensive losses — 24,000 — — — — — 11,600 —

(Losses)/gains on available for sale debt securities included in earnings (3) — ( 67,800 ) 62,885 6,900 — — — 1,300 16,559

Other non-operating expense — — — — — ( 6,715 ) — — —

Settlement of forwards (4) — 79,585 ( 79,585 ) — — — — 18,459 ( 18,459 )

Transfer out of Level 3 (5) ( 40,692 ) — — — — — — — —

Redemptions (1) — ( 542,044 ) — — — — — ( 62,500 ) —

Balance at the end of the year $ 8,472 $ 227,600 $ — $ ( 2,500 ) $ 96,610 $ 14,500 $ 43,013 $ 253,700 $ 16,700

(1) For the year ended December 31, 2021, the unrealized gains on available for sale debt securities is comprised of $ 11.6 million related to Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income and $ 1.3 million related to the Series B Biohaven Preferred Shares as recorded on the consolidated statements of operations.

For the year ended December 31, 2020, the unrealized gains on available for sale debt securities related to the Series A Biohaven Preferred Shares as recorded on the consolidated statements of comprehensive income, including $ 52.7 million prior to transferring out of Level 3 and then $ 15.9 million after transferring back to Level 3.

(2) Reflects the fair value attributed to the Series B Forwards that were settled in the period as the Series B Biohaven Preferred Shares were acquired, which is included in the fair value of the Series B Biohaven Preferred Shares.

See Note 3–Available for Sale Debt Securities.

(3) Includes $ 14.5 million of unrealized gains on available for sale debt securities included in other comprehensive income while the Series A Biohaven Preferred Shares was classified as a Level 2 asset.

(4) Recorded within Unrealized gains on available for sale debt securities on the consolidated statements of operations.

Valuation inputs

Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.

(1) Following Pfizer’s acquisition of Biohaven in October 2022, we purchased all remaining unissued Series B Biohaven Preferred Shares and we received accelerated redemption payments for all outstanding Series A Biohaven Preferred Shares and Series B Biohaven Preferred Shares.

(2) Reflects the purchase price allocation for the long-term funding agreement entered into with Cytokinetics to arrive at the appropriate fair value of the Cytokinetics Funding Commitments on initial recognition.

Amounts also reflect the losses on initial recognition of debt securities related to the difference in (a) the fair value of the Additional Funding of the Development Funding Bonds and (b) the actual additional funded amount of $ 150 million.

(3) Amounts reflect changes in the fair values of the Series B Biohaven Preferred Shares, Series B Forwards and the Development Funding Bond Forward.

For 2022, amounts also reflect the change in the fair value of the funded portion of the Cytokinetics Commercial Launch Funding, the funded portion of the Development Funding Bonds and the Cytokinetics Funding Commitments.

(4) Amounts reflect the fair value attributed to the Series B Forwards that were settled as we acquired the Series B Biohaven Preferred Shares.

Amounts in 2022 also reflect the fair value attributed to the Development Funding Bond Forward that was settled upon funding the Development Funding Bonds.

(5) Related to the expiration of the transfer restriction on BioCryst common stock.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Investment in Series A Biohaven Preferred Shares

The fair value of the Series A Biohaven Preferred Shares as of December 31, 2021 and 2020 was based on the cash flows due to us from Biohaven of two times the original purchase price of the Series A Biohaven Preferred Shares payable in equal quarterly installments of $ 15.6 million following the FDA approval and starting one-year after FDA approval, through December 31, 2024.

The FDA approved Nurtec ODT in February 2020, at which point we became entitled to receive a fixed payment amount of $ 250.0 million payable in equal quarterly payments from March 31, 2021 through December 31, 2024.

The fair value of the Series A Biohaven Preferred Shares as of December 31, 2021 and 2020 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which would result in accelerated payments and redemptions.

Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate requires significant judgement.

Our estimate of a risk adjusted discount rate of 9.5 % and 8.3 % as of December 31, 2021 and 2020, respectively, could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower.

Prior to February 2020, we measured our investment in the Series A Biohaven Preferred Shares using a Black-Derman- Toy lattice model, which included the use of Level 3 fair value measurements and inputs.

In February 2020, when Nurtec ODT received FDA approval, we began measuring the fair value of the Series A Biohaven Preferred Shares using a discounted cash flow analysis that relied on observable inputs, and therefore, we transferred the Series A Biohaven Preferred Shares from a Level 3 to a Level 2 asset.

During the three months ended December 31, 2020, information pertaining to Biohaven’s issuance of debt and its effective interest rate became available and we refined our valuation of the Series A Biohaven Preferred shares as of December 31, 2020 to incorporate this significant unobservable input.

As a result, we reclassified the investment from a Level 2 to a Level 3 asset during the three months ended December 31, 2020.

Valuation Inputs for Recurring Fair Value Measurements

Below is a discussion of the valuation inputs used for financial instruments classified as Level 2 and Level 3 measurements in the fair value hierarchy.

ApiJect Investment

We utilized the discounted cash flow method using Level 3 inputs, including forecasted cash flows and the weighted average cost of capital, to estimate the fair value as of December 31, 2022 of the equity securities and revenue participation right that we acquired from ApiJect Holdings, Inc.

(“ApiJect”), a private company, in April 2022.

Our estimate of the forecasted cash flows and the weighted average cost of capital could reasonably be different than those selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower.

Refer to Note 9–Non-Consolidated Affiliates for additional discussion.

Cytokinetics Commercial Launch Funding & Funding Commitments

We estimated the fair value of the funded Cytokinetics Commercial Launch Funding as of December 31, 2022 by utilizing probability-adjusted discounted cash flow calculations using Level 3 inputs, including an estimated risk-adjusted discount rate and the probability that there will be a change of control event, which would result in accelerated payments.

Developing a risk-adjusted discount rate and assessing the probability that there will be a change of control event over the duration of the Cytokinetics Commercial Launch Funding require significant judgement.

Our estimate of the risk-adjusted discount rate could reasonably be different than the discount rate selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower.

Our expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than the timing of an actual change of control event, and if so, would mean that the estimated fair value could be significantly higher or lower than the fair value determined by management at any particular date.

We estimated the fair value of the Cytokinetics Funding Commitments as of December 31, 2022 using a Monte Carlo simulation methodology that includes simulating the interest rate movements using a Geometric Brownian Motion-based pricing model.

This methodology simulates the likelihood of future discount rates exceeding the counterparty’s assumed cost of debt, which would impact Cytokinetics’ decision to exercise its option to draw on each respective tranche.

This methodology incorporates Level 3 fair value measurements and inputs, including an assumed interest rate volatility of 30 % and an assumed risk-adjusted discount rate of 13.5 %.

We also assumed probabilities for the occurrence of each regulatory or clinical milestone, which impacts the availability of each future tranche of funding.

Our estimate of the risk-adjusted discount rate, the interest rate volatility and the probabilities of each underlying milestone could reasonably be different than the assumptions selected by a market participant, which would mean that the estimated fair value could be significantly higher or lower.

BioCryst Common Stock

In November 2021, we purchased 3,846 thousand shares of common stock of BioCryst Pharmaceuticals, Inc.

(“BioCryst”).

As part of the transaction, we were restricted from selling the BioCryst common stock for six months following the close of the transaction.

We determined the fair value of the BioCryst common stock as of December 31, 2021 based on the closing stock price and adjusted for the transfer restriction, which was determined by calculating the value of a put option over the common stock to match the duration of the transfer restriction.

This methodology incorporated Level 3 inputs, including the estimated volatility of the BioCryst common stock, which required significant judgement.

Our estimated volatility could be reasonably different than the actual volatility of BioCryst’s common stock, which would mean that the estimated fair value for the common stock could be significantly higher or lower than the fair value determined by management at any particular date.

During the second quarter of 2022, the transfer restriction expired and the BioCryst common stock was transferred from a Level 3 to a Level 1 asset.

MorphoSys Development Funding Bonds & Forward

The fair values of the Development Funding Bonds and the Development Funding Bond Forward as of December 31, 2022 and 2021 were based on a discounted cash flow calculation using estimated risk-adjusted discount rates, which are Level 3 fair value inputs.

Our estimate of the risk adjusted discount rates could reasonably be different than the discount rates selected by a market participant, which would mean that the estimated fair values could be significantly higher or lower.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Investment in Series B Biohaven Preferred Shares

The fair value of the Series B Biohaven Preferred Shares and Series B Forwards as of December 31, 2021 and the fair value of the Series B Forwards as of December 31, 2020 were based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions.

Assessing the probability that there will be a change of control event over the duration of the Series B Biohaven Preferred Shares and developing a risk-adjusted discount rate requires significant judgement.

Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series B Biohaven Preferred Shares or the Series B Forwards, which would mean that the estimated fair value could be significantly higher or lower.

MorphoSys Development Funding Bonds

The fair value of the Development Funding Bond Forward as of December 31, 2021 was based on a discounted cash flow calculation using an estimated risk-adjusted discount rate, which is a Level 3 fair value input.

Our estimate of a risk adjusted discount rate could reasonably be different than the discount rate selected by a market participant in the event of a sale of the instrument, which would mean that the estimated fair value could be significantly higher or lower.

We have elected the fair value option to account for the Development Funding Bond Forward as it most accurately reflects the nature of the instrument.

BioCryst Equity Securities

In November 2021, we purchased 3,846 thousand shares of common stock in BioCryst Pharmaceuticals, Inc.(“BioCryst”), which was calculated based on the volume-weighted average price of BioCryst common stock over a period preceding the closing of the transaction.

As part of the transaction, we are restricted from selling the common stock for six months following the close of the transaction.

The fair value of the BioCryst common stock as of December 31, 2021 was based on the closing stock price and adjusted for the transfer restriction, which was determined by calculating the value of a put option over the common stock to match the duration of the transfer restriction.

This methodology includes the use of Level 3 inputs, including the estimated volatility of the BioCryst common stock, which requires the use of significant judgement.

Our estimated volatility could be reasonably different than the actual volatility for the common stock which would mean that the estimated fair value for the common stock could be significantly higher or lower than the fair value determined by management at any particular date.

Series A Biohaven Preferred Shares

The Series A Biohaven Preferred Shares were redeemed following Pfizer’s acquisition of Biohaven in October 2022.

The fair value of the Series A Biohaven Preferred Shares as of December 31, 2021 was calculated using probability-adjusted discounted cash flow calculations incorporating Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability of a change of control event occurring during the investment term, which results in accelerated payments and redemptions.

Assessing the probability that there will be a change of control event over a four-year time period and developing a risk-adjusted discount rate require significant judgement.

Our estimate of a risk adjusted discount rate of 9.5 % as of December 31, 2021 could reasonably be different than the discount rate selected by a market participant in the event of a sale of the Series A Biohaven Preferred Shares, which would mean that the estimated fair value could be significantly higher or lower.

Series B Biohaven Preferred Shares & Forwards

All remaining unissued Series B Biohaven Preferred Shares were purchased simultaneously with the redemption of all outstanding Series B Biohaven Preferred Shares following Pfizer’s acquisition of Biohaven in October 2022.

The fair value of each of the Series B Biohaven Preferred Shares and Series B Forwards as of December 31, 2021 was based on probability-adjusted discounted cash flow calculations using Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rates and the probability that there will be a change of control event in different periods of time, which would result in accelerated payments and redemptions.

Our estimate of a risk adjusted discount rate, expectation of the probability and timing of the occurrence of a change of control event could reasonably be different than those determined by a market participant, which would mean that the estimated fair value could be significantly higher or lower.

Milestone Acceleration Option

We estimated the fair value of the Milestone Acceleration Option as of December 31, 2022 using the “with-and-without” methodology, which is a variation of the income approach and is based on the difference between cash flows for two different scenarios.

The prospective cash flows for the success-based milestone payments include the Milestone Acceleration Option in the first scenario.

For the second scenario, the prospective cash flows are estimated assuming they remain payable over time.

The difference between the fair value of these two scenarios represents the fair value of the Milestone Acceleration Option.

This methodology includes the use of Level 3 fair value measurements and inputs, including estimated risk-adjusted discount rate which was primarily based on Pfizer’s cost of debt and management’s estimated probabilities of achieving the success-based milestones.

Assessing the likelihood that the success-based milestones are achieved over the duration of the Milestone Acceleration Option and developing a risk-adjusted discount rate require significant judgement.

Our estimate of a risk adjusted discount rate and the probabilities of achieving marketing approval could reasonably be different than those determined by a market participant, which would mean that the estimated fair value could be significantly higher or lower.

The fair value associated with this instrument was not material prior to the second quarter of 2022, when Pfizer announced its intended acquisition of Biohaven.

Other Financial Instruments

We use third party pricing services for Level 2 inputs used to value cash equivalents, marketable securities, derivative instruments and borrowings, which provide documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information.

Warrants are valued using a Black-Scholes option pricing model which considers observable and unobservable inputs.

Financial instruments whose fair values are measured on a recurring basis using Level 2 inputs primarily consist of commercial paper, certificates of deposit and U.S.

government securities.

We measure the fair value of these financial instruments with the help of third-party pricing services that provide quoted market prices in active markets for similar securities or observable inputs for their pricing without applying significant adjustments.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Financial Assets Not Measured at Fair Value

Financial royalty assets are measured and carried on the consolidated balance sheets at amortized cost using the effective interest method.

The fair value of financial royalty assets is calculated by management using the forecasted royalty payments we expect to receive based on the projected product sales for all royalty bearing products as estimated by sell-side equity research analysts’ consensus sales forecasts or, where such consensus sales forecasts are not available, management uses reasonable judgment to make assumptions about the projected product sales.

The current portion of financial royalty assets approximates fair value.

Management calculates the fair value of financial royalty assets using the forecasted royalty payments that are expected to be received based on the projected product sales for all royalty bearing products which are estimated using sell-side equity research analysts’ consensus sales forecasts.

These projected future royalty payments by asset, along with any projected incoming or outgoing milestone payments, are then discounted to a present value using appropriate individual discount rates.

The fair value of our financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable.

Estimated fair values based on Level 3 inputs and related carrying values for our financial royalty assets as of December 31, 2021 and 2020 are presented below (in thousands).

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2021 December 31, 2020

The fair value of financial royalty assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable.

The estimated fair values and related carrying values of the non-current portion of financial royalty assets as of December 31, 2022 and 2021 are presented below (in thousands):

As of December 31, 2022 As of December 31, 2021

Fair Value Carrying Value, net Fair Value Carrying Value, net

Financial royalty assets, net $ 17,314,094 $ 13,493,106 $ 19,047,183 $ 13,718,245

Financial Royalty Assets, Net

Financial royalty assets, net consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.

The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets at December 31, 2021 and 2020 are as follows (in thousands):

Financial Royalty Assets

Financial royalty assets consist of contractual rights to cash flows relating to royalty payments derived from the expected sales of patent-protected biopharmaceutical products that entitle us and our subsidiaries to receive a portion of income from the sale of such products by third parties.

The gross carrying value, cumulative allowance for changes in expected cash flows, exclusive of the allowance for credit losses, and net carrying value for the current and non-current portion of financial royalty assets as of December 31, 2022 and 2021 are as follows (in thousands):

As of December 31, 2022

Estimated Royalty Duration (a) Gross Carrying Value Cumulative Allowance for Changes in Expected Cash Flows (Note 7) Net Carrying Value (e)

Cystic fibrosis franchise 2037 (b) $ 5,335,641 $ ( 48,636 ) $ 5,287,005

Tysabri (c) 1,846,069 ( 16,617 ) 1,829,452

Estimated Royalty Duration (1)

Gross Carrying Value Cumulative Allowance for Changes in Expected Cash Flows (Note 7) Net Carrying Value (4)

Cystic fibrosis franchise 2037 (2)

$ 5,333,535 $ ( 10,908 ) $ 5,322,627

1,683,441 ( 212,283 ) 1,471,158

Trelegy 2029-2030 1,284,054 ( 24,126 ) 1,259,928

Tremfya 2031-2032 894,160 — 894,160

Imbruvica 2027-2032 1,436,969 ( 660,703 ) 776,266

Xtandi 2027-2028 1,009,168 ( 235,625 ) 773,543

Tremfya 2031-2032 881,671 — 881,671

Evrysdi 2030-2035 (d) 727,774 — 727,774

Other 2023-2041 5,134,980 ( 1,332,815 ) 3,802,165

1 unchanged sentence

Cumulative allowance for credit losses (Note 7) ( 115,422 )

Total financial royalty assets, net $ 14,332,596

(a) Dates shown represent our estimates as of current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography.

Total current and non-current financial royalty assets, net $ 14,184,425

(1) Durations shown represent our estimates as of the current reporting date of when a royalty will substantially end, which may depend on clinical trial results, regulatory approvals, contractual terms, commercial developments, estimates of patent expiration dates (which may include estimated patent term extensions) or other factors and may vary by geography.

There can be no assurances that our royalties will expire when expected.

(b) Royalty is perpetual;

(2) Royalty is perpetual;

year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.

Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.

(d) Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $ 1.3 billion.

(e) The net carrying value by asset is presented before the allowance for credit losses.

(3) RPIFT acquired a perpetual royalty on net sales of Tysabri.

We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.

(4) The net carrying value by asset is presented before the allowance for credit losses.

Refer to Note 7–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

During the fourth quarter of 2022, we recorded $ 160.1 million and $ 273.6 million of non-cash impairment charges for otilimab and gantenerumab, respectively, both unapproved financial royalty assets held at cost.

The impairment charges were recorded as a result of GSK plc’s announcement that it has decided not to progress with regulatory submissions for otilimab and Roche’s statement that it would discontinue clinical trials of gantenerumab.

Included in the total financial royalty assets balance of $ 14.2 billion as of December 31, 2022, is $ 533.8 million related to unapproved financial assets held at cost:

zavegepant, seltorexant and olpasiran.

Additionally, during the fourth quarter of 2022, we impaired our financial royalty asset related to Gavreto and recorded a non-cash impairment charge of $ 182.1 million due to the uncertainty of Gavreto’s commercial outlook.

These impairment charges were recorded within Financial royalty asset impairment in the consolidated statements of operations.

As of December 31, 2021

Estimated Royalty Duration (a) Gross Carrying Value Cumulative Allowance for Changes in Expected Cash Flows (Note 7) Net Carrying Value (e)

Cystic fibrosis franchise 2037 (b) $ 5,274,896 $ — $ 5,274,896

Tysabri (c) 2,003,797 ( 112,720 ) 1,891,077

Estimated Royalty Duration (1)

Gross Carrying Value Cumulative Allowance for Changes in Expected Cash Flows (Note 7) Net Carrying Value (5)

Cystic fibrosis franchise 2037 (2)

$ 5,335,641 $ ( 48,636 ) $ 5,287,005

1,846,069 ( 16,617 ) 1,829,452

Imbruvica 2027-2032 1,438,730 ( 236,871 ) 1,201,859

Xtandi 2027-2028 1,100,065 ( 172,101 ) 927,964

Promacta 2025-2028 686,129 — 686,129

Evrysdi 2030-2035 (d) 675,440 — 675,440

Tremfya 2031-2032 881,671 — 881,671

Evrysdi 2030-2035 (4)

727,774 — 727,774

Other 2023-2041 4,697,591 ( 909,916 ) 3,787,675

1 unchanged sentence

Cumulative allowance for credit losses (Note 7) ( 310,804 )

Total financial royalty assets, net $ 12,955,277

Total current and non-current financial royalty assets, net $ 14,332,596

There can be no assurances that our royalties will expire when expected.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(b) Royalty is perpetual;

(2) Royalty is perpetual;

year shown represents Trikafta expected patent expiration and potential sales decline based on timing of potential generic entry.

Management has applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.

(d) Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $ 1.3 billion.

(e) The net carrying value by asset is presented before the allowance for credit losses.

(3) RPIFT acquired a perpetual royalty on net sales of Tysabri.

We have applied an end date of 2031 for purposes of accreting income over the royalty term, which is periodically reviewed.

(4) Key patents on Evrysdi in the United States expire in 2035, but our royalty will cease when aggregate royalties paid to us equal $ 1.3 billion.

(5) The net carrying value by asset is presented before the allowance for credit losses.

Refer to Note 7–Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets for additional information.

Cumulative Allowance and the Provision for Changes in Expected Cash Flows from Financial Royalty Assets

The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of Financial royalty assets, net on the consolidated balance sheets and includes the following activities:

• the movement in the cumulative allowance related to changes in forecasted royalty payments we expect to receive based on projected product sales for royalty bearing products as estimated by sell-side equity research analysts’ consensus sales forecasts , and

• the movement in the cumulative allowance for current expected credit losses.

The periodic movement in the cumulative allowance is presented on the consolidated statements of operations as the Provision for changes in expected cash flows from financial royalty assets .

The current period provision for changes in expected cash flows from financial royalty assets reflects the activity for the period primarily new financial royalty assets and changes in the underlying cash flow forecasts used in the effective interest model to measure income from our financial royalty assets.

Refer to Note 2 – Summary of Significant Accounting Policies for further information.

The cumulative allowance for changes in expected future cash flows from financial royalty assets is presented net within the non-current portion of financial royalty assets on the consolidated balance sheets and includes the following activities:

• the movement in the cumulative allowance related to changes in forecasted royalty payments expected to be received based on projected product sales for royalty bearing products which are estimated using sell-side equity research analysts’ consensus sales forecasts,

• the write-off of cumulative allowance at the end of a royalty asset’s life which only impacts the consolidated balance sheets, and

• the movement in the cumulative allowance for current expected credit losses, primarily associated with new financial royalty assets with limited protective rights and changes in the underlying cash flow forecasts of financial royalty assets with limited protective rights .

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

The following table sets forth the activity in the cumulative allowance for changes in expected cash flows from financial royalty assets, inclusive of the cumulative allowance for credit losses, as of the dates indicated (in thousands):

1 unchanged sentence

Balance at December 31, 2019 $ ( 868,418 )

Cumulative adjustment for adoption of ASU 2016-13 ( 192,705 )

Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets ( 645,612 )

Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets 570,959

Write-off of cumulative allowance (a) 95,158

Write-off of cumulative allowance 2,964

Write-off of credit loss allowance (1) 25,174

Provision for credit losses, net (2) ( 156,186 )

Balance at December 31, 2020 $ ( 1,263,824 )

Cumulative adjustment for adoption of ASU 2016-13 ( 192,705 )

Increases to the cumulative allowance for changes in expected cash flows from financial royalty assets ( 912,710 )

Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets 446,955

Write-off of cumulative allowance (a) 2,964

Write-off of credit loss allowance (b) 25,174

Current period provision expense for credit losses, net (c) ( 156,186 )

Write-off of cumulative allowance 21,721

Provision for credit losses, net (2) 12,913

Balance at December 31, 2021 $ ( 1,694,945 )

1 unchanged sentence

Decreases to the cumulative allowance for changes in expected cash flows from financial royalty assets 296,637

Write-off of cumulative allowance (a) 21,721

Current period provision income for credit losses, net (c) 12,913

Write-off of cumulative allowance 5,723

Write-off of credit loss allowance 1,584

Provision for credit losses, net (2) 193,798

Balance at December 31, 2022 $ ( 2,591,882 )

(a) Relates to amounts removed from the allowance at the end of a royalty asset’s life to bring the account balance to zero.

Write-offs solely impact the asset account and allowance account;

there is no impact on the consolidated statements of operations.

(b) Relates to amounts reversed out of the credit loss allowance associated with omecamtiv mecarbil as a result of the write-off of the related financial royalty asset balance of $ 90.2 million.

(c) In the year ended December 31, 2020, the provision for credit losses was primarily related to certain additions to our portfolio of financial royalty assets with limited protective rights in 2020, mainly the final tranche of Tazverik.

In the year ended December 31, 2021,the provision income for credit losses was primarily related to a significant decline in the financial asset value for Tazverik, which was offset by increases in our portfolio of financial royalty assets with limited protective rights in 2021, primarily related to zavegepant.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(1) Relates to amounts reversed out of the credit loss allowance associated with omecamtiv mecarbil as a result of the gross write-off of the related financial royalty asset balance of $ 90.2 million.

(2) For 2020, the provision for credit losses was primarily related to certain additions to our portfolio of financial royalty assets with limited protective rights, mainly the final tranche of Tazverik.

For 2021, the provision income for credit losses was primarily related to a significant decline in value of Tazverik, which was offset by increases in the value of zavegepant.

For 2022, the provision income for credit losses was primarily related to further declines in the value of Tazverik and changes in the payors for certain products with stronger credit profiles, which were partially offset by the addition of Trelegy to our portfolio of financial royalty assets with limited protective rights.

Intangible Royalty Assets, Net

The following schedules of the intangible royalty assets present the cost, accumulated amortization and net carrying value as of December 31, 2021 and 2020 (in thousands).

As of December 31, 2021 Cost Accumulated Amortization Net Carrying Value

DPP-IV patents $ 606,216 $ 600,546 $ 5,670

Total intangible royalty assets $ 606,216 $ 600,546 $ 5,670

As of December 31, 2022, the intangible royalty assets were fully amortized as our royalties on Januvia and Janumet expired in the first quarter of 2022.

Our royalties on the other DPP-IV products have also substantially ended.

As of December 31, 2021, the cost, accumulated amortization and net carrying value of our intangible royalty assets are summarized as below (in thousands):

As of December 31, 2021 Cost Accumulated Amortization Net Carrying Value

1 unchanged sentence

Total intangible royalty assets $ 606,216 $ 600,546 $ 5,670

The majority of our DPP-IV patents associated with the intangible royalty assets terminate at various dates through 2022.

The weighted average remaining life of the intangible royalty assets is less than one year .

We project amortization expense will be $ 5.7 million in 2022.

Our revenue is tied to underlying patent protected sales of DPP-IV products of various licensees.

Such revenue from royalty assets is earned from sales occurring primarily in the United States and Europe;

however, we do not have the ability to disaggregate our royalty revenue from licensees based on the geography of the underlying sales, as this level of information is not always included in royalty reports provided to us.

The marketers paying us royalties on these products do not always provide, and are not necessarily required to provide, the breakdown of product sales by geography.

Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 86 %, 97 % and 91 % of our revenues from intangible royalty assets in the years ended December 31, 2021, 2020 and 2019, respectively.

Revenue from intangible assets is tied to underlying patent protected sales of DPP-IV products of various licensees.

Such revenue is earned from sales occurring primarily in the United States and Europe;

however, we do not have the ability to disaggregate such revenue from licensees based on the geography of the underlying sales as this information may not be provided to us by marketers.

Individual licensees exceeding 10% or more of revenue from intangible royalty assets accounted for 90 %, 86 % and 97 % of revenues from intangible royalty assets in 2022, 2021 and 2020, respectively.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Non-Consolidated Affiliates

We have equity investments in certain entities at a level that provide us with significant influence.

We account for such investments as equity method investments or as equity securities over which we have elected the fair value option.

In 2022, we acquired common stock and a revenue participation right from ApiJect.

We elected the fair value option to account for our investments in ApiJect because it is more reflective of current values for such investments.

We are also required to purchase additional common stock from ApiJect if certain milestones are achieved.

The fair value of our equity investment in ApiJect was recorded within Equity securities as of December 31, 2022 and the change in fair value was recorded within (Gains)/losses on equity securities for 2022.

The fair value of the revenue participation right was recorded within Other assets as of December 31, 2022 and the change in fair value was recorded within Other non-operating expense, net for 2022.

No amounts were due from ApiJect as of December 31, 2022.

The Legacy SLP Interest

3 unchanged sentences

Our income allocation is equal to the general partner’s former contractual rights to the income of the Legacy Investors Partnerships, net of amortization of the basis difference.

The Legacy SLP Interest is treated as an equity method investment as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence.

The Legacy SLP Interest is accounted for under the equity method as our Manager is also the Manager of the Legacy Investors Partnerships and has the ability to exercise significant influence.

The Legacy Investors Partnerships no longer participate in investment opportunities from June 30, 2020 and, as such, the value of the Legacy SLP Interest is expected to decline over time.

The Legacy Investors Partnerships also own a non-controlling interest in Old RPI.

The Legacy Investors Partnerships also indirectly own a non-controlling interest in Old RPI and RPI ICAV.

The income allocation from the Legacy SLP Interest is based on an estimate as the Legacy Investors Partnerships are private partnerships that are expected to report on a lag subsequent to the date of this annual report.

Management’s estimate of equity in earnings from the Legacy SLP Interest for the current period will be updated for historical results in the subsequent period.

During the years ended December 31, 2021 and 2020, we recorded an income allocation of $ 8.9 million and $ 62.0 million, respectively, within Equity in losses/(earnings) of non-consolidated affiliates .

We received cash distributions from the Legacy SLP Interest of $ 21.0 million and $ 22.7 million during the years ended December 31, 2021 and 2020, respectively.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

We recorded income allocations of $ 3.0 million, $ 8.9 million and $ 62.0 million within Equity in losses/(earnings) of equity method investees in 2022, 2021 and 2020, respectively.

We collected cash receipts from the Legacy SLP Interest of $ 25.7 million, $ 21.0 million and $ 22.7 million during 2022, 2021 and 2020, respectively.

The Avillion Entities

We account for our partnership interests in Avillion Financing I, LP (“Avillion I”) and BAv Financing II, LP (“Avillion II”, or, together, the “Avillion Entities”) as equity method investments because RPIFT has the ability to exercise significant influence over the entities.

We recorded a loss allocation from the Avillion Entities of $ 28.4 million, $ 17.6 million and $ 32.5 million within Equity in losses/(earnings) of non-consolidated affiliates during the years ended December 31, 2021, 2020 and 2019, respectively.

We account for our partnership interests in Avillion Financing I, LP and its related entities (“Avillion I”) and BAv Financing II, LP and its related entities (“Avillion II” and, together with Avillion I, the “Avillion Entities”) as equity method investments because RPIFT has the ability to exercise significant influence over the Avillion Entities.

We recorded loss allocations from the Avillion Entities of $ 12.0 million, $ 28.4 million and $ 17.6 million within Equity in losses/(earnings) of equity method investees in 2022, 2021 and 2020, respectively.

On December 19, 2017, the FDA approved a supplemental New Drug Application for Pfizer’s Bosulif.

Avillion I is eligible to receive fixed payments from Pfizer based on this approval.

Subsequent to the asset sale, the only operations of Avillion I are the collection of cash and unwinding of discount on the series of fixed annual payments due from Pfizer.

We received distributions from Avillion I of $ 13.4 million during each of the years ended December 31, 2021 and 2020, and $ 14.1 million in the year ended December 31, 2019 in connection with Avillion I’s receipt of the fixed annual payments due under its co-development agreement with Pfizer.

In March 2017, RPIFT entered into an agreement with Avillion II, which was amended in 2019, to invest approximately $ 19.0 million to fund approximately 50 % of the costs of a Phase 2 clinical trial for the use of Merck KGaA’s anti-IL 17 nanobody M1095 (the “Merck KGaA Asset”) for the treatment of psoriasis in exchange for certain milestone and royalty payments.

Our involvement in the development for the Merck KGaA Asset ceased in the year ended December 31, 2020, for which we received a distribution of $ 21.3 million from Avillion II.

In May 2018, RPIFT entered into an additional agreement, which was amended in July 2021, to increase our investment up to $ 122.5 million from $ 105.0 million in Avillion II over multiple years to fund approximately 44 % of the costs of Phase 2 and 3 clinical trials to advance PT027 through a global clinical development program for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments.

As of December 31, 2021 and 2020, RPIFT had $ 11.2 million and $ 28.6 million respectively, of unfunded commitments related to the Avillion Entities.

Our maximum exposure to loss at any particular reporting date is limited to the current carrying value of the investment plus the unfunded commitments.

Research & Development (“R&D”) Funding Expense

R&D funding expense consists of upfront and ongoing R&D payments we have made to counterparties to acquire royalties and/or milestones on development-stage product candidates.

Ongoing R&D payments are made as the related development-stage product candidates undergo clinical trials with our counterparties.

During the year ended December 31, 2021, 2020, and 2019 we did not enter into any new ongoing R&D funding arrangements.

We recognized R&D funding expense of $ 200.1 million during the year ended December 31, 2021, comprised of $ 6.9 million in ongoing R&D expenses, primarily under our co-funding agreement with Sanofi, and $ 193.2 million in upfront R&D funding.

As part of a long-term strategic funding partnership with MorphoSys, which closed on July 15, 2021 (as further discussed in Note 17 – Commitments and Contingencies), we allocated $ 90.0 million of the upfront payment to R&D funding expense, representing two development-stage products acquired in exchange for future royalties.

Additionally, we made an upfront payment of $ 103.2 million to BioCryst to acquire a royalty on a development-stage product in November 2021.

We recognized R&D funding expense of $ 26.3 million during the year ended December 31, 2020, of which $ 20.5 million related to ongoing development-stage funding payments, primarily under our co-funding agreement with Sanofi and $ 5.8 million related to upfront funding for a royalty on a development-stage product that we acquired from BioCryst.

We recognized $ 83.0 million of R&D funding expense during the year ended December 31, 2019, of which $ 18.2 million and $ 62.8 million related to our funding agreements with both Sanofi and Pfizer, respectively.

We completed our funding commitments in the fourth quarter of 2019 under our agreement with Pfizer.

We did not have upfront development-stage R&D funding expense in 2019.

As of December 31, 2021, we have a remaining commitment of $ 10.7 million related to our R&D funding agreement with Sanofi.

Avillion I is eligible to receive fixed payments from Pfizer based on this approval under its co-development agreement with Pfizer.

The only operations of Avillion I are the collection of cash and unwinding of the discount on the series of fixed annual payments due from Pfizer.

We received distributions from Avillion I of $ 13.4 million in each of 2022, 2021 and 2020.

In May 2018, RPIFT entered into an agreement with Avillion II, which was amended in July 2021 and June 2022, to fund a total of $ 150.0 million over multiple years for a portion of the costs of Phase 2 and 3 clinical trials to advance Airsupra, formerly known as PT027, which was approved by the FDA in January 2023.

Avillion II is a party to a co-development agreement with AstraZeneca to develop Airsupra for the treatment of asthma in exchange for royalties, a series of success-based milestones and other potential payments.

In January 2023, AstraZeneca notified Avillion II that it elected to pay a fee of $ 80 million to Avillion II to exercise an option to commercialize Airsupra in the United States.

We expect to receive our pro rata portion of the exercise fee of approximately $ 35 million, subject to any holdback for expenses, in 2023.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Our borrowings at December 31, 2021 and 2020 consisted of the following (in thousands):

Type of Borrowing Date of Issuance Maturity December 31, 2021 December 31, 2020

Our maximum exposure to loss at any particular reporting date is limited to the carrying value of our equity method investments plus the unfunded commitments.

As of December 31, 2022 and 2021, RPIFT had unfunded commitments related to the Avillion Entities of $ 28.8 million and $ 11.2 million, respectively.

Research & Development (“R&D”) Funding Expense

R&D funding expense consists of payments that we have made to counterparties to acquire royalties or milestones on product candidates.

It includes development-stage funding payments that are made upfront or upon pre-approval milestones and development-stage funding payments that are made over time as the related product candidates undergo clinical trials with our counterparties.

We recognized R&D funding expense of $ 177.1 million in 2022 , primarily related to upfront and milestone development-stage funding payments of $ 100.0 million, $ 25.0 million and $ 50.0 million to acquire royalties on development-stage products from Cytokinetics, Theravance Biopharma, Inc., and MSD International Business GmbH, respectively.

We recognized R&D funding expense of $ 200.1 million in 2021, comprised of $ 193.2 million in upfront R&D funding expense and $ 6.9 million in ongoing R&D funding expense, primarily under our co-funding agreement with Sanofi.

The upfront R&D funding expense included $ 103.2 million and $ 90.0 million in exchange for an incremental royalty on a development-stage product from BioCryst and future royalties on two development-stage products from MorphoSys, respectively.

We recognized R&D funding expense of $ 26.3 million in 2020, comprised of $ 20.5 million in ongoing R&D funding expense, primarily under our co-funding agreement with Sanofi, and $ 5.8 million in upfront R&D funding expense for a royalty on a development-stage product that we acquired from BioCryst.

Our borrowings as of December 31, 2022 and 2021 consisted of the following (in thousands):

Type of Borrowing Date of Issuance Maturity As of December 31, 2022 As of December 31, 2021

Senior Unsecured Notes:

21 unchanged sentences

On July 26, 2021, we issued $ 1.3 billion of senior unsecured notes (the “2021 Notes”) comprised of $ 600.0 million principal amount of notes due September 2031 and $ 700.0 million principal amount of notes due September 2051.

Interest on each series of the 2021 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, beginning on March 2, 2022.

Interest on each series of the 2021 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year, which began on March 2, 2022.

The 2021 Notes were issued at a total discount of $ 27.5 million and we capitalized approximately $ 12.3 million in debt issuance costs primarily composed of underwriting fees.

The 2021 Notes have a weighted average coupon rate and a weighted average effective interest rate of 2.80 % and 3.06 %, respectively.

The 2021 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.80 % and 3.06 %, respectively.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

On September 2, 2020, we issued $ 6.0 billion of senior unsecured notes (the “2020 Notes” and, together with the 2021 Notes, the “Notes”).

We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the senior secured credit facilities.

We used the net proceeds from the 2020 Notes offering, together with available cash on hand, to repay in full the outstanding principal amounts of term loans under our prior senior secured credit facilities.

Interest on each series of the 2020 Notes accrues at the respective rate per annum and is payable semi-annually in arrears on March 2 and September 2 of each year.

The 2020 Notes were issued at a total discount of $ 149.0 million and we capitalized approximately $ 40.4 million in debt issuance costs primarily comprised of underwriting fees.

The 2020 Notes have a weighted average coupon rate and a weighted average effective interest rate of 2.125 % and 2.50 %, respectively.

The 2020 Notes were issued with a weighted average coupon rate and a weighted average effective interest rate of 2.13 % and 2.50 %, respectively.

On August 3, 2021, we completed an exchange offer for the 2020 Notes where certain holders elected to tender their unregistered outstanding notes for freely tradable exchange notes that were registered under the Securities Act of 1933.

2 unchanged sentences

Upon the occurrence of a change of control triggering event and downgrade in the rating of our Notes by two of three credit agencies, the holders may require us to repurchase all or part of their Notes at a price equal to 101 % of the aggregate principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to the date of repurchase.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Our obligations under the Notes are fully and unconditionally guaranteed by RP Holdings, a non-wholly owned subsidiary.

We are required to comply with certain covenants under our Notes and as of December 31, 2022, we were in compliance with all applicable covenants.

As of December 31, 2021 and 2020, the estimated fair value of our outstanding Notes using Level 2 inputs was approximately $ 7.2 billion and $ 6.2 billion, respectively.

As of December 31, 2022 and 2021, the fair value of our outstanding Notes using Level 2 inputs was approximately $ 5.7 billion and $ 7.2 billion, respectively.

Senior Unsecured Revolving Credit Facility

On September 15, 2021, we entered into an amended and restated revolving credit agreement (the “Credit Agreement”).

The Credit Agreement amends and restates the existing credit agreement that our subsidiary, RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the “Revolving Credit Facility”) with borrowing capacity of up to $ 1.5 billion for general corporate purposes.

The Credit Agreement extends the maturity of the Revolving Credit Facility to September 15, 2026.

On September 15, 2021, we entered into an amended and restated revolving credit agreement, which was further amended on October 31, 2022 (the “Credit Agreement”).

The Credit Agreement amended and restated the prior credit agreement that our subsidiary, RP Holdings, as borrower, entered into on September 18, 2020, which provided for a five-year unsecured revolving credit facility (the “Revolving Credit Facility”) with borrowing capacity of up to $ 1.5 billion for general corporate purposes.

The Revolving Credit Facility has a maturity date of October 31, 2027.

As of December 31, 2022 and 2021, there were no outstanding borrowings under the Revolving Credit Facility.

The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent’s prime rate, (2) the federal funds effective rate and the overnight bank funding rate, plus 0.5 % and (3) the one month adjusted LIBOR, plus 1 % or (b) the Eurocurrency Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin.

The Revolving Credit Facility is subject to an interest rate, at our option, of either (a) a base rate determined by reference to the highest of (1) the administrative agent’s prime rate, (2) the federal funds rate plus 0.5 % and (3) Term SOFR plus 1 % or (b) Daily SOFR, Term SOFR, the Alternative Currency Term Rate or the Alternative Currency Daily Rate (each as defined in the Credit Agreement), plus in each case, the applicable margin.

The applicable margin for the Revolving Credit Facility varies based on our public debt rating.

2 unchanged sentences

All obligations under the Revolving Credit Facility are unconditionally guaranteed by us.

Noncompliance with the leverage ratio and interest coverage ratio covenants under the Credit Agreement could result in our lenders requiring us to immediately repay all amounts borrowed.

The Credit Agreement includes customary covenants for credit facilities of this type that limit our ability to engage in certain activities, such as incurring additional indebtedness, paying dividends, making certain payments and acquiring and disposing of assets.

As of December 31, 2022, RP Holdings was in compliance with these covenants.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Senior Secured Credit Facilities

3 unchanged sentences

In September 2020, we repaid in full the outstanding principal amounts of term loans under the senior secured credit facilities with net proceeds from the 2020 Notes and available cash on hand.

Upon refinancing our senior secured credit facilities in September 2020, we recorded a loss on debt extinguishment of $ 25.1 million as part of Other non-operating expense/(income), net, which primarily consisted of unamortized loan issuance costs and original issue discount related to our senior secured credit facilities.

Upon refinancing our senior secured credit facilities in September 2020, we recorded a loss on debt extinguishment of $ 25.1 million as part of Other non-operating expense, net, which primarily consisted of unamortized loan issuance costs and original issue discount related to our senior secured credit facilities.

RPIFT Senior Secured Credit Facilities

The RPIFT Senior Secured Credit Facilities were repaid in full in February 2020 in connection with the Exchange Offer Transactions.

We recorded a loss on debt extinguishment of $ 5.4 million as part of Other non-operating expense/(income), net during the year ended December 31, 2020.

We recorded a loss on debt extinguishment of $ 5.4 million as part of Other non-operating expense, net in 2020.

Principal Payments on the Notes

The future principal payments for our borrowings as of December 31, 2022 over the next five years and thereafter are as follows (in thousands):

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Year Principal Payments

1 unchanged sentence

2025 1,000,000

2027 1,000,000

Thereafter 4,300,000

7 unchanged sentences

Our Class B ordinary shares are not publicly traded and holders of Class B ordinary shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding up of the Company.

An exchange agreement entered into by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the “Exchange Agreement”) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares.

As of December 31, 2022, we have 443,166 thousand Class A ordinary shares and 164,058 thousand Class B ordinary shares outstanding.

An exchange agreement entered into in connection with the IPO by us, RP Holdings, the Continuing Investors Partnerships, RPI International Partners 2019, LP and EPA Holdings (the “Exchange Agreement”) governs the exchange of RP Holdings Class B Interests held by the Continuing Investors Partnerships for Class A ordinary shares.

Pursuant to the Exchange Agreement, RP Holdings Class B interests are exchangeable on a one -for-one basis for Class A ordinary shares on a quarterly basis.

As of December 31, 2021, we have outstanding 432,963 thousand Class A ordinary shares and 174,213 thousand Class B ordinary shares.

Each such exchange also results in the re-designation of the same number of our Class B ordinary shares as deferred shares.

As of December 31, 2021, we have outstanding deferred shares of 361,170 thousand.

In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights.

The purpose of the Class R redeemable shares was to ensure Royalty Pharma Limited had sufficient sterling denominated share capital at the time it was re-registered as a public limited company to Royalty Pharma plc, as required by the U.K.

Companies Act.

The Class R redeemable shares may be redeemed at our option in the future.

As of December 31, 2022, we have 371,325 thousand deferred shares outstanding.

In addition, we have in issue 50 thousand Class R redeemable shares, which do not entitle the holder to voting or dividend rights.The Class R redeemable shares may be redeemed at our option in the future.

Any such redemption would be at the nominal value of £ 1 each.

2 unchanged sentences

Non-Controlling Interests

The only non-controlling interest in the year ended December 31, 2019 related to RPSFT, for which the net change in the related balance is as presented in the statements of shareholders’ equity.

The net change in the balance of our four non-controlling interests for the years ended December 31, 2021 and 2020 is as follows (in thousands):

The changes in the balance of our four non-controlling interests for 2022, 2021 and 2020 are as follows (in thousands):

RPSFT Legacy Investors Partnerships Continuing Investors Partnerships (1) EPA Holdings Total

10 unchanged sentences

Unrealized gains on available for sale debt securities — 15,015 7,488 — 22,503

Reclassification of unrealized losses on available for sale debt securities — ( 3,612 ) ( 6,018 ) — ( 9,630 )

Reclassification of unrealized gains on available for sale debt securities — ( 3,612 ) ( 6,018 ) — ( 9,630 )

December 31, 2020 $ 12,436 $ 1,939,509 $ 3,125,091 $ — $ 5,077,036

(1) Related to the Continuing Investors Partnerships’ ownership of approximately 36 % in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2020.

Royalty Pharma plc owns the remaining 64 % of RP Holdings through its ownership of RP Holdings Class A Interests and Class B Interests as of December 31, 2020.

RPSFT Legacy Investors Partnerships Continuing Investors Partnerships (1) EPA Holdings Total

Contributions — 35,148 13,391 — 48,539

Distributions ( 56,490 ) ( 425,050 ) ( 133,433 ) — ( 614,973 )

Other exchanges — — ( 642,974 ) — ( 642,974 )

Net income 57,582 266,570 297,321 — 621,473

Other comprehensive income/(loss):

Unrealized gains on available for sale debt securities — 2,038 3,227 — 5,265

Reclassification of unrealized gains on available for sale debt securities — ( 8,946 ) ( 13,469 ) — ( 22,415 )

December 31, 2021 $ 13,528 $ 1,809,269 $ 2,649,154 $ — $ 4,471,951

5 unchanged sentences

Unrealized gains on available for sale debt securities — 4,218 5,520 — 9,738

Reclassification of unrealized losses on available for sale debt securities — ( 8,946 ) ( 13,469 ) — ( 22,415 )

Reclassification of unrealized gains on available for sale debt securities — ( 9,392 ) ( 12,160 ) — ( 21,552 )

December 31, 2022 $ ( 597 ) $ 1,527,887 $ 2,369,933 $ — $ 3,897,223

(1) Related to the Continuing Investors Partnerships’ ownership of approximately 29 % in RP Holdings through their ownership of the RP Holdings Class B Interests as of December 31, 2021.

Royalty Pharma plc owns the remaining 71 % of RP Holdings through its ownership of RP Holdings Class A Interests and Class B Interests as of December 31, 2021.

(1) Related to the Continuing Investors Partnerships’ ownership of approximately 27 %, 29 % and 36 % in RP Holdings through their ownership of RP Holdings Class B Interests as of December 31, 2022, 2021 and 2020, respectively.

Royalty Pharma plc owns the remaining and 73 %, 71 % and 64 % of RP Holdings through its ownership of RP Holdings Class A Interests and RP Holdings Class B Interests as of December 31, 2022, 2021 and 2020, respectively.

ROYALTY PHARMA PLC

1 unchanged sentence

RP Holdings Class C Special Interest Held by EPA Holdings

EPA Holdings is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis.

Investments made during each two-year period will be grouped together as separate portfolios (each, a “Portfolio”).

EPA Holdings, an affiliate of the Manager, is entitled to Equity Performance Awards (as defined below) through its RP Holdings Class C Special Interest based on our performance, as determined on a portfolio-by-portfolio basis.

Investments made during each two-year period are grouped together as separate portfolios (each, a “Portfolio”).

Subject to certain conditions, at the end of each fiscal quarter, EPA Holdings is entitled to a distribution from RP Holdings in respect of each Portfolio equal to 20% of the Net Economic Profit (defined as the aggregate cash receipts for all new portfolio investments in such Portfolio less Total Expenses (defined as interest expense, operating expense and recovery of acquisition cost in respect of such Portfolio)) for such Portfolio for the applicable measuring period (the “Equity Performance Awards”).

The Equity Performance Awards will be allocated and paid by RP Holdings to EPA Holdings as the holder of the RP Holdings Class C Special Interest.

The Equity Performance Awards will be payable in RP Holdings Class B Interests for which we will issue the same number of Class B ordinary shares, which may be subsequently exchanged for our Class A ordinary shares.

We do not currently expect any material Equity Performance Awards to be payable until the performance conditions discussed above are met.

The holders of Class A ordinary shares are entitled to receive dividends subject to approval by the board of directors.

The Equity Performance Awards will be payable in RP Holdings Class B Interests that will be exchanged upon issuance for Class A ordinary shares.

EPA Holdings may also receive a periodic cash advance in respect of the RP Holdings Class C Special Interest to the extent necessary for EPA Holdings or any of its beneficial owners to pay when due any income tax imposed on it or them as a result of holding such RP Holdings Class C Special Interest.

We do not expect any material Equity Performance Awards to be payable until certain performance conditions discussed above are met.

Similarly, we do not expect any material income to be allocated to EPA Holdings until such performance conditions are met.

The holders of Class A ordinary shares are entitled to receive dividends subject to approval by our board of directors.

The holders of Class B ordinary shares do not have any rights to receive dividends;

however the RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings, our consolidated subsidiary.

In the year ended December 31, 2021, we declared and paid four quarterly cash dividends of $ 0.17 per Class A ordinary share for an aggregate amount of $ 285.2 million to holders of our Class A ordinary shares .

however, RP Holdings Class B Interests are entitled to dividends and distributions from RP Holdings.

During 2022, we declared and paid four quarterly cash dividends of $ 0.19 per Class A ordinary share for an aggregate amount of $ 333.3 million to holders of our Class A ordinary shares .

2020 Independent Directors Equity Incentive Plan

3 unchanged sentences

We grant RSUs to our independent directors under the 2020 Independent Director Equity Incentive Plan.

Share-based compensation expense is recognized based on estimated fair value of the award on the grant date and amortized on a straight-line basis over the requisite service period of generally one year as part of General and administrative expenses in the consolidated statement of comprehensive income.

The estimated fair value of RSUs is based on the closing price of our Class A ordinary shares on the grant date.

We recognized share-based compensation of approximately $ 3.1 million and $ 5.7 million for the years ended December 31, 2021 and 2020, which is recorded as part of General and administrative expenses in the consolidated statement of operations.

There were no share-based awards or related expenses in periods prior to the IPO.

In 2022, 2021 and 2020, respectively, we did not recognize material share-based compensation expense.

As of December 31, 2022, the total unrecognized share-based compensation expense related to total outstanding RSUs was less than $ 1.0 million, which we expect to recognize in the next six months .

Earnings per Share

Basic earnings per share (“EPS”) is computed by dividing net income attributable to us by the weighted average number of Class A ordinary shares outstanding during the period.

Diluted EPS is computed by dividing net income attributable to us, including the impact of potentially dilutive securities, by the weighted average number of Class A ordinary shares outstanding during the period, including the number of Class A ordinary shares that would have been outstanding if the potentially dilutive securities had been issued.

Potentially dilutive securities include the outstanding Class B ordinary shares, Class B ordinary shares contingently issuable to EPA Holdings related to Equity Performance Awards, and unvested RSUs issued under our Equity Incentive Plan.

We use the “if-converted” method to determine the potentially dilutive effect of our outstanding Class B ordinary shares, and the treasury stock method to determine the potentially dilutive effect of the unvested RSUs.

For 2022, 2021 and 2020, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact.

Additionally, Class B ordinary shares in issue were evaluated under the if-converted method for potential dilutive effects and were determined to be anti-dilutive for 2022, 2021 and 2020, and therefore were excluded from the computation of diluted earnings per shares of Class A ordinary share.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Our Class B ordinary shares, Class R redeemable shares, and deferred shares do not share in the earnings or losses attributable to us and are therefore not participating securities.

As such, separate presentation of basic and diluted earnings per share for Class B ordinary shares, Class R redeemable shares, and deferred shares under the two-class method has not been presented.

Our Class B ordinary shares are, however, considered potentially dilutive shares of Class A ordinary shares because shares of Class B ordinary shares, together with the related RP Holdings Class B Interests, are exchangeable into Class A ordinary shares on a one -for-one basis.

For the years ended December 31, 2021 and 2020, Class B ordinary shares contingently issuable to EPA Holdings were evaluated and were determined not to have any dilutive impact.

Additionally, Class B ordinary shares in issue were evaluated under the if-converted method for potential dilutive effects and were determined to be anti-dilutive for the years ended December 31, 2021 and 2020, and therefore were excluded from the computation of diluted earnings per shares of Class A ordinary share.

As of December 31, 2021 and 2020, we had 607,176 thousand and 607,111 thousand fully diluted Class A ordinary shares outstanding, respectively.

The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted earnings per Class A ordinary share for the year ended December 31, 2021 (in thousands, except per share amounts).

Year Ended December 31, 2021

The following tables set forth reconciliations of the numerators and denominators used to calculate basic and diluted earnings per Class A ordinary share for 2022, 2021 and 2020 (in thousands, except per share amounts):

Years Ended December 31,

Consolidated net income $ 230,064 $ 1,241,201

9 unchanged sentences

We analyzed the calculation of earnings per interest for periods prior to the IPO and determined that the resultant values would not be meaningful to the users of these consolidated financial statements.

Therefore, the basic and diluted earnings per share for the year ended December 31, 2020 are only applicable for the period from June 16, 2020 to December 31, 2020, which represents the period in which we had outstanding Class A ordinary shares.

December 31, 2020

Therefore, the basic and diluted earnings per share for 2020 are only applicable for the period from June 16, 2020 to December 31, 2020, which represents the period in which we had outstanding Class A ordinary shares.

Year Ended December 31,

Consolidated net income $ 1,701,954

8 unchanged sentences

Earnings per Class A ordinary share - diluted $ 1.32

(1) Reflected as Net income attributable to controlling interest on the consolidated statements of operations .

(1) Reflected as Net income attributable to Royalty Pharma plc on the consolidated statements of operations.

ROYALTY PHARMA PLC

11 unchanged sentences

Amortization of debt discount and issuance costs 21,356 20,162 11,715

Losses on derivative financial instruments 21,532 42,076 39,138

(Gains)/losses on derivative financial instruments ( 96,610 ) 21,532 42,076

Losses/(gains) on equity securities 33,442 48,066 ( 247,073 )

Equity in losses/(earnings) of non-consolidated affiliates 19,490 ( 44,459 ) 32,517

Distributions from non-consolidated affiliates 34,384 42,334 14,059

Equity in losses/(earnings) of equity method investees 8,973 19,490 ( 44,459 )

Distributions from equity method investees 39,142 34,384 42,334

Loss on extinguishment of debt 419 358 30,272

1 unchanged sentence

Interest income accretion ( 53,432 ) ( 50,896 ) ( 20,551 )

Unrealized gains on available for sale debt securities ( 17,859 ) ( 18,600 ) —

Impairment charge — 65,053 —

Losses/(gains) on available for sale debt securities 6,815 ( 17,859 ) ( 18,600 )

Financial royalty asset impairment 615,827 — 65,053

Termination of derivative financial instruments — ( 16,093 ) ( 34,952 )

2 unchanged sentences

Cash collected on financial royalty assets 2,507,236 2,315,854 2,121,923

Available for sale debt securities — — ( 150,000 )

Accrued royalty receivable 36,456 ( 20,131 ) 370

Other receivables — — 150,000

Other royalty income receivable ( 4,744 ) ( 9,012 ) ( 770 )

Other current assets and other assets 1,857 34,986 ( 41,028 )

(Decrease)/increase in operating liabilities:

Other current assets 2,198 1,857 34,986

Increase/(decrease) in operating liabilities:

Accounts payable and accrued expenses 2,286 ( 4,586 ) ( 766 )

6 unchanged sentences

Receipt of contribution of investment in Legacy Investors Partnerships (Note 9) $ — $ — $ 303,679

Settlement of Epizyme forward purchase contract — 5,700 —

Accrued purchase obligation - Tazverik (Note 17) — 110,000 —

Repayments of long-term debt by contributions from non-controlling interest (1) — 1,103,774 —

Settlement of Epizyme forward purchase contract (Note 4) — — 5,700

Accrued purchase obligation - Tazverik (1) — — 110,000

Repayments of long-term debt by contributions from non-controlling interests (2) — — 1,103,774

Milestone payable - Erleada (3) 12,400 — 18,600

(1) Related to our obligation under our agreement with Eisai to fund the final tranche of the Tazverik royalty for $ 110.0 million following the June 2020 FDA approval of additional indications of Tazverik.

(2) Related to the pro rata portion of RPIFT’s outstanding debt repaid by the Legacy Investors Partnerships.

(2) Related to the achievement of a sales-based milestone that was not paid as of December 31, 2020 as recorded within Other current liabilities on the consolidated balance sheet.

(3) Related to the achievement of sales-based milestones that were not paid as of December 31, 2022 and 2020.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Accumulated Other Comprehensive Income

As of December 31, 2021 and 2020, the only component of accumulated other comprehensive income related to the Unrealized gains on available for sale debt securities on the Series A Biohaven Preferred Shares.

As a result of the termination of interest rate swaps in February 2020, all amounts associated with interest rate swaps previously designated as cash flow hedges and recorded in Accumulated other comprehensive income were released into earnings.

The components of accumulated other comprehensive income as of December 31, 2021 and 2020 are as follows (in thousands):

Unrealized Gains on Available for Sale Debt Securities Unrealized Losses on Interest Rate Swaps Total Accumulated Other Comprehensive Income

Balance at December 31, 2019 6,159 ( 4,066 ) 2,093

Reclassification to net income ( 10,921 ) 4,066 ( 6,855 )

Activity for the year 60,617 — 60,617

Reclassification to non-controlling interest ( 24,022 ) — ( 24,022 )

Reclassification from non-controlling interest 2,562 — 2,562

Balance at December 31, 2020 34,395 — 34,395

Reclassification to net income ( 28,481 ) — ( 28,481 )

Activity for the year 6,335 — 6,335

Reclassification from non-controlling interest 4,242 — 4,242

Balance at December 31, 2021 $ 16,491 $ — $ 16,491

The total reclassification of unrealized gains on available for sale debt securities of $ 50.9 million in the year ended December 31, 2021 is presented within Interest incom e on the consolidated statements of operations, including $ 28.5 million attributable to controlling interest noted in the table above and $ 22.4 million attributable to the non-controlling interest.

The total reclassification of unrealized gains on available for sale debt securities of $ 20.6 million in the year ended December 31, 2020 is presented within Interest incom e on the consolidated statements of operations, including $ 10.9 million attributable to controlling interest noted in the table above and $ 9.6 million attributable to the non-controlling interest.

Commitments and Contingencies

Funding Commitments

We have various funding commitments as of December 31, 2022 and 2021.

See Note 3–Available for Sale Debt Securities for discussion of the respective arrangements.

Cytokinetics Commercial Launch Funding

As of December 31, 2022, $ 250 million of the Cytokinetics Commercial Launch Funding remained unfunded.

Other Commitments

We have commitments to advance funds to counterparties through our investment in the Avillion Entities.

Please refer to Note 9–Non-Consolidated Affiliates for details of these arrangements.

We also have requirements to make Operating and Personnel Payments over the life of the Management Agreement as described in Note 16–Related Party Transactions.

Indemnifications

In the ordinary course of our business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts.

The maximum exposure under such agreements is indeterminable until a claim, if any, is made.

However, no such claims have been made against us to date and we believe that the likelihood of such proceedings taking place in the future is remote.

Legal Proceedings

We are a party to legal actions with respect to a variety of matters in the ordinary course of business.

Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages.

Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings on our consolidated balance sheets as of December 31, 2022 and 2021.

When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved.

We do not believe the outcome of any existing legal proceedings to which we are a party, either individually or in the aggregate, will adversely affect our business, financial condition or results of operations.

Related Party Transactions

The Manager is the investment manager of Royalty Pharma and its subsidiaries.

The Manager is an affiliate of RP Ireland, the administrator of RPIFT, RPI Intermediate FT and RPSFT.

The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of the board of directors, and as a director on the board of directors of RP Holdings.

In connection with the Exchange Offer Transactions (discussed in Note 1–Organization and Purpose), the Manager entered into Management Agreements with us and our subsidiaries, the Continuing Investors Partnerships, and with the Legacy Investors Partnerships.

Pursuant to the Management Agreements, we pay quarterly operating and personnel expenses to the Manager or its affiliates (“Operating and Personnel Payments”) equal to 6.5 % of the Adjusted Cash Receipts (both, as defined in the Management Agreement) for such quarter and 0.25 % of the value of our security investments under GAAP as of the end of such quarter.

The operating and personnel payments for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected in our consolidated net income, is calculated as the greater of $ 1 million per quarter and 0.3125 % of Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months.

The Manager is the investment manager of Royalty Pharma plc and its subsidiaries.

The sole member of the Manager, Pablo Legorreta, holds an interest in us and serves as our Chief Executive Officer and Chairman of our board of directors.

In connection with the Exchange Offer Transactions (discussed in Note 1–Organization and Purpose), the Manager entered into the Management Agreement with us and our subsidiaries, the Continuing Investors Partnerships, and with the Legacy Investors Partnerships.

Pursuant to the Management Agreement, we pay a quarterly operating and personnel payment to the Manager or its affiliates (“Operating and Personnel Payments”) equal to 6.5 % of the cash receipts from royalty investments for such quarter and 0.25 % of the value of our security investments under GAAP as of the end of such quarter.

The operating and personnel payment for Old RPI, an obligation of the Legacy Investors Partnerships as a non-controlling interest in Old RPI and for which the expense is reflected on our consolidated net income, is calculated as the greater of $ 1 million per quarter and 0.3125 % of royalties from Royalty Investments (as defined in the limited partnership agreements of the Legacy Investor Partnerships) during the previous twelve calendar months.

Additionally, we also pay certain costs and expenses of the Manager.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Prior to the Exchange Date, the Manager received operating and personnel payments payable in equal quarterly installments that increased by 5 % annually on a compounded basis under the terms of its management agreement with Old RPI and the Legacy Investors Partnerships.

RP Ireland receives an annual management fee payable in advance by Old RPI in equal quarterly installments under terms of the limited partnership agreements of the Legacy Investors Partnerships.

After the Exchange Date, operating and personnel payments were calculated in accordance with the methodology discussed in the paragraph above.

During the years ended December 31, 2021, 2020 and 2019, total operating and personnel payments incurred were $ 145.2 million, $ 112.5 million and $ 60.0 million, respectively, including the amounts attributable to Old RPI, and were recognized within General and administrative expenses on the consolidated statements of operations.

Distribution Payable to Non-Controlling Interest

The distribution payable to non-controlling interest represents the contractual cash flows required to be distributed based on the Legacy Investors Partnerships’ non-controlling interest in Old RPI and RPSFT’s non-controlling interest in RPCT.

The distribution payable to non-controlling interest as of December 31, 2021 and 2020 included the following (in thousands).

December 31, 2021 December 31, 2020

Prior to the date of the Exchange Offer, the Manager received operating and personnel payments payable in equal quarterly installments that increased by 5 % annually on a compounded basis under the terms of its management agreement with Old RPI and the Legacy Investors Partnerships.

The Manager or its affiliates receive an annual management fee payable in advance by Old RPI in equal quarterly installments under terms of the limited partnership agreements of the Legacy Investors Partnerships.

During 2022, 2021 and 2020, total operating and personnel payments incurred were $ 188.4 million, $ 145.2 million and $ 112.5 million, respectively, including the amounts attributable to Old RPI, and were recognized within General and administrative expenses in the consolidated statements of operations.

Distributions Payable to Legacy Non-Controlling Interests

The distributions payable to legacy non-controlling interests represent the contractual cash flows required to be distributed based on the Legacy Investors Partnerships’ non-controlling interest in Old RPI and RPI ICAV and RPSFT’s non-controlling interest in RPCT.

The distributions payable to legacy non-controlling interests as of December 31, 2022 and 2021 include the following (in thousands):

As of December 31, 2022 As of December 31, 2021

Due to Legacy Investors Partnerships $ 87,522 $ 92,608

Due to RPSFT 7,281 15,326

Total distribution payable to non-controlling interest $ 107,934 $ 126,366

Acquisition from Epizyme

In November 2019, in connection with a royalty acquisition and an equity investment in Epizyme made by RPIFT, Pablo Legorreta, our Chief Executive Officer, was appointed as a director of Epizyme, for which he received, and continues to receive, compensation in cash and shares of Epizyme, all of which are and will continue to be contributed to the Manager and used to reduce costs and expenses which would otherwise be billed to us or our affiliates.

We continue to hold Epizyme common stock as of December 31, 2021.

Total distributions payable to legacy non-controlling interests $ 94,803 $ 107,934

Acquisition from Bristol Myers Squibb

In November 2017, RPI Acquisitions, a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (“BMS”) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the “Purchase Agreement”).

We agreed to make payments to BMS based on sales of the products over eight quarters beginning with the first quarter of 2018 in exchange for a high single-digit royalty on worldwide sales of the products from 2020 through 2025.

On December 8, 2017, RPI Acquisitions entered into a purchase, sale and assignment agreement (“Assignment Agreement”) with a wholly owned subsidiary of BioPharma Credit PLC (“BPCR”), an affiliate of us.

We considered BPCR as a related party due to the sole member of the Manager having significant influence over BPCR’s investment manager.

In November 2017, RPI Acquisitions (Ireland), Limited (“RPI Acquisitions”) , a consolidated subsidiary, entered into a purchase agreement with Bristol Myers Squibb (“BMS”) to acquire from BMS a percentage of its future royalties on worldwide sales of Onglyza, Farxiga and related diabetes products marketed by AstraZeneca (the “Purchase Agreement”).

Under the terms of the Assignment Agreement, RPI Acquisitions assigned the benefit of 50 % of the payment stream acquired from BMS to BPCR in consideration for BPCR meeting 50 % of the funding obligations owed to BMS under the Purchase Agreement.

We began making installment payments to BMS in 2018 and completed our funding requirement, net of the assigned funding obligations, totaling $ 162.4 million in the three months ended March 31, 2020.

We began to measure this financial royalty asset using the effective interest method once our installment funding obligation was completed and we received our first royalty payment in the three months ended June 30, 2020.

As of December 31, 2021 and 2020, the financial royalty asset of $ 130.9 million and $ 150.6 million, respectively, included in Financial royalty assets, net on the consolidated balance sheets represents only our right to the future payment streams acquired from BMS.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2022 and 2021, the financial royalty asset of $ 103.4 million and $ 130.9 million, respectively, on the consolidated balance sheets represents only our right to the future payment streams acquired from BMS.

Other Transactions

Henry Fernandez, the lead independent director of our board of directors, serves as the chairman and chief executive officer of MSCI, Inc (“MSCI”).

On April 16, 2021, we entered into an agreement with MSCI with an initial term of seven years to assist MSCI in the design of a classification framework and index methodologies in order to expand MSCI’s thematic index suite with the launch of new indexes.

On April 16, 2021, we entered into an agreement with MSCI with an initial term of seven years to develop thematic life sciences indexes.

In return, we will receive a percentage of MSCI’s revenues from those indexes.

No amounts were due from MSCI as of December 31, 2021.

The financial statement impact associated with this transaction was not material for the year ended December 31, 2021.

In the year ended December 31, 2020, we reimbursed Pablo Legorreta approximately $ 1.0 million for the cost of purchasing and donating ventilators to hospitals on behalf of Royalty Pharma.

In connection with the Exchange Offer Transactions, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary.

No amounts were due from MSCI as of December 31, 2022 and 2021.

The financial impact associated with this transaction has not been material to date.

During 2020, we reimbursed Pablo Legorreta approximately $ 1.0 million for the cost of purchasing and donating ventilators to hospitals on behalf of Royalty Pharma.

In connection with the Exchange Offer, we acquired the Legacy SLP Interest from the Continuing Investors Partnerships in exchange for issuing shares in our subsidiary.

As a result, we became a special limited partner in the Legacy Investors Partnerships.

The Legacy Investors Partnerships own a non-controlling interest in Old RPI.

Refer to Note 9–Non-Consolidated Affiliates for additional discussion.

RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnership whose only substantive operations are their investment in our subsidiaries.

The total investment of $ 4.3 million is recorded as treasury interests, of which $ 1.6 million and $ 1.9 million are held by non-controlling interest as of December 31, 2021 and 2020, respectively.

Based on its ownership percentage of RP Holdings relative to the Company, each Continuing Investor Partnership pays a pro rata portion of any costs and expenses in connection with the contemplation of, formation of, listing and ongoing operation of us and any of our subsidiaries, including any third-party expenses of managing us and any of our subsidiaries, such as accounting, audit, legal, reporting, compliance, administration (including directors’ fees), financial advisory, consulting, investor relations and insurance expenses relating to our affairs and those of any subsidiary.

Commitments and Contingencies

In the ordinary course of its business, we may enter into contracts or agreements that contain customary indemnifications relating to such things as confidentiality agreements and representations as to corporate existence and authority to enter into contracts.

The maximum exposure under such agreements is indeterminable until a claim, if any, is made.

However, no such claims have been made against us to date and we believe that the likelihood of such proceedings taking place in the future is remote.

On June 2, 2021, we announced a long-term strategic funding partnership with MorphoSys to support MorphoSys’ acquisition of Constellation, which closed on July 15, 2021.

As part of the funding agreement, we agreed to make additional milestone payments of up to $ 150.0 million and provide up to $ 350.0 million of Development Funding Bonds, which MorphoSys may draw over a one-year period from the close of its acquisition of Constellation.

MorphoSys is required to draw a minimum of $ 150.0 million, for which we have recognized the Development Funding Bond Forward within Available for sale debt securities on the consolidated balance sheet as of December 31, 2021 (See Note 3–Available for Sale Debt Securities for additional discussion).

As of December 31, 2021, MorphoSys has not drawn any amount under the Development Funding Bonds.

On August 7, 2020, we entered into a funding agreement with Biohaven, including the Series B Biohaven Preferred Share Agreement, to fund the development of zavegepant and the commercialization of Nurtec ODT in exchange for royalties and success-based milestones.

Pursuant to the Series B Biohaven Preferred Share Agreement, we agreed to provide further support for the ongoing launch of Nurtec ODT with the purchase of committed, non-contingent Commercial Launch Preferred Equity for a total of $ 200.0 million payable on a quarterly basis between March 31, 2021 and December 31, 2024.

In return, Biohaven will be required to redeem the Series B Biohaven Preferred Shares in a series of equal fixed quarterly payments between March 31, 2025 and December 31, 2030.

During the three months ended March 30, 2021, we began purchasing the Series B Biohaven Preferred Shares.

We have a remaining commitment of $ 129.6 million under the Commercial Launch Preferred Equity, for which we have recognized the Series B Forwards within Available for sale debt securities on the consolidated balance sheet as of December 31, 2021.

See Note 3–Available for Sale Debt Securities for additional discussion.

The Legacy Investors Partnerships own a non-controlling interest in Old RPI and RPI ICAV.

Refer to Note 9–Non-Consolidated Affiliates for additional discussion of the Legacy SLP Interest and our investments in other non-consolidated entities.

RPIFT owns 27,210 limited partnership interests in the Continuing Investors Partnerships, whose only substantive operations are their investment in our subsidiaries.

The total investment of $ 4.3 million was recorded as treasury interests, of which $ 1.5 million and $ 1.6 million were held by non-controlling interests as of December 31, 2022 and 2021, respectively.

ROYALTY PHARMA PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

In November 2019, RPIFT agreed to pay $ 330.0 million to purchase Eisai’s royalties on future worldwide sales of Tazverik, a novel targeted therapy in late-stage clinical development that was approved by the FDA in January 2020 for epithelioid sarcoma, and with the potential to be approved in several cancer indications.

Under the terms of our agreement with Eisai, we acquired Eisai’s future worldwide royalties on net sales by Epizyme of Tazverik outside of Japan, for an upfront payment of $ 110.0 million plus up to an additional $ 220.0 million for the remainder of the royalty upon FDA approval of Tazverik for certain indications.

The FDA approval of Tazverik in January 2020 triggered our obligation to fund the second $ 110.0 million tranche in November 2020.

On November 4, 2021, we funded the final $ 110.0 million tranche.

We have commitments to advance funds to counterparties through our investment in the Avillion Entities and R&D arrangements.

Please refer to Note 9–Non-Consolidated Affiliates and Note 10–Research & Development (“R&D”) Funding Expense, respectively, for details of these arrangements.

We also have requirements to make Operating and Personnel Payments over the life of the management agreement as described in Note 16–Related Party Transactions, which are variable and primarily based on cash receipts.

Legal Proceedings

We are a party to legal actions with respect to a variety of matters in the ordinary course of business.

Some of these proceedings may be based on complex claims involving substantial uncertainties and unascertainable damages.

Unless otherwise noted, it is not possible to determine the probability of loss or estimate damages, and therefore we have not established accruals for any of these proceedings in our consolidated balance sheets as of December 31, 2021 and 2020.

When we determine that a loss is both probable and reasonably estimable, we record a liability, and, if the liability is material, we disclose the amount of the liability reserved.

Subsequent Events

In January 2022, we acquired a royalty interest in aficamten from Cytokinetics, Incorporated (“Cytokinetics”) for $ 150.0 million, comprised of an upfront payment of $ 50 million and two additional $ 50 million payments which are conditional upon the initiation of potential pivotal clinical trials for obstructive hypertrophic cardiomyopathy and nonobstructive hypertrophic cardiomyopathy, respectively.

Additionally, we will provide Cytokinetics long-term capital of up to $ 300 million (“Cytokinetics Commercial Launch Funding”) to support further development of aficamten and potential commercialization of omecamtiv mecarbil.

The Cytokinetics Commercial Launch Funding is available in five tranches, including an initial tranche of $ 50 million funded upon closing and four additional tranches in the aggregate amount of $ 250 million upon the occurrence of certain regulatory and clinical development milestones.

In January 2023, we acquired an interest in Ionis Pharmaceuticals, Inc.’s royalty in Biogen’s Spinraza (nusinersen) and Novartis’ pelacarsen, a development-stage product, for up to $ 1.125 billion, including an upfront payment of $ 500 million and up to $ 625 million in additional pelacarsen milestone payments.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 8. Financial Statements and Supplementary Data